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Chen J. Page 1 Summary
A. SUMMARY
If we are to exploit more fully the potential of proteins for clinical and industrial 
applications (as in vivo diagnostic and therapeutic agents, as research tools, as 
components of biosensors, and perhaps later as components of nanomachines 
or as high-performance texile fibers, etc.) we must consider chemical 
modification. Over the years, some very mild and effective techniques (e.g. 
oxime chemistry) have been developed which permit the modification of proteins 
without damaging their intricate structure. In this way, part of a protein which has 
a desired function (as enzymatic activity, or ability to localize in tumor tissue, for 
example) is cut out and "pasted” together with some other structures which may 
themselves be proteins or may be synthetic drugs (drugs to kill tumor cells, for 
example) or may be other substances grafted for other purposes, such as 
poly(ethyleneglycol) to extend biological half-life and reduce immunogenicity, a 
fluorescent dye reporter group, a lipid to modulate immunological properties, or 
even nucleic acid for gene therapy applications. The functions of each of the 
several components can be preserved, and in spite of its size and complexity, the 
resulting product can be homogeneous, which is desirable for clinical use.
In a more drastic approach, only the minimum structural elements required for 
binding are preserved (or mimicked) and the rest of the macromolecule is 
replaced with linkers such as short poly(ethyleneglycol) chains.
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The scope of the research undertaken has been to develop ‘nuts and bolts’ 
protein engineering at the protein level to build useful and complex structures 
through site-specific reactions: in general, oxime chemistry. In particular:
(1) I investigated the effect of peptide multiplicity on immunogenicity using a 
model peptide from the envelope protein gp120 of Human Immunodeficiency 
Virus type-1.
(2) I used cholera toxin B subunit (CTB) as a model to study the effect (structural 
and biological) of attaching a cascade of immunogenic peptides to the N- 
terminus.
(3) I increased the avidity and specificity of small peptide ligands through a 
cluster (multivalency) approach.
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B. INTRODUCTION
1. Vaccines and Vaccination
Vaccines have been known for a long time to save a lot of lives and money since 
the first vaccine to prevent smallpox, an infectious disease, emerged in China in 
the 6th century, when scabs were taken from patients, dried, ground and then 
blown into the nostrils of humans [1]. However, it was not practical to vaccinate 
large populations until the 1870s when Pasteur made significant progress on the 
attenuation of the chicken cholera virus [2]. He observed that live attenuated 
vaccines to cowpox and smallpox consisted of a weaker form of the same 
organism but did not cause related diseases. Since then vaccination has had a 
very important impact on the prevalence of some infectious diseases. Nowadays, 
vaccine research is not only focusing on new initiatives for the well recognized 
infectious diseases but is also creating new projects on vaccines to prevent and 
treat autoimmune diseases and cancers [3].
Vaccines are made from antigens of pathogens. They may be natural or 
attenuated living organisms, intact but non-living organisms, sub-cellular 
fragments, toxoids, recombinant DNA, or anti-idiotype antigens. In general, the 
more antigens of the microbe retained in the vaccine, the better. Living
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organisms tend to be more effective than killed ones [4]. The approaches to 
vaccination that have been tried are listed in Table 1.
Table 1: Vaccine Approaches
Types of Vaccine Examples
Live attenuated or killed bacteria BCG (Bacillus Calmette-Guerin), cholera
Live attenuated viruses Polio, rabies
Subunit (antigen) vaccines Tetanus toxoid, diphtheria toxoid
Conjugate vaccines Haemophilus influenzae, pneumococcus
Synthetic Vaccines Hepatitis (recombinant proteins)
Viral vectors Clinical trials of HIV antigens in 
canarypox vector
DNA vaccines Clinical trials ongoing for several 
infectious diseases
2. Artificial proteins as vaccines
Proteins and polypeptides function in Nature in a remarkable variety of ways, and 
have been used extensively in clinical and industrial applications as in vivo 
diagnostic and therapeutic agents, as research tools and as components of 
biosensors. Many proteins made for such applications result from recombinant 
DNA technology (e.g. granulocyte colony stimulating factor, G-CSF, 
erythropoietin, EPO). Some polypeptides are chemically synthesized (e.g.
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calcitonin) and some products involve both recombinant techniques and 
chemistry (e.g. human insulin, made by chemical and enzymatic transformation 
of a precursor generated in yeast). These chemical applications have been 
greatly facilitated by recent advances in techniques of protein purification, 
characterization and synthesis [5]. Some applications have benefited from the 
development of solid-phase peptide synthesis pioneered by Merrifield [6] and 
from proteins that have been modified chemically, due to the fact that the 
diversity of protein behavior is sometimes influenced by even minor variations in 
molecular structure [7].
Synthetic peptides have been demonstrated to induce antibodies that can react 
with their cognate sequences in native proteins [8,9]. For this reason, a synthetic 
peptide can serve as an immunogen to produce passive immunoprophylaxis [8- 
11] or can be used to induce antipeptide antibodies useful as laboratory 
reagents, for example in the study of biosynthetic pathways by confirming de 
novo synthesis of proteins from recombinant DNA [9]. However, a small linear 
peptide may not be effective as an immunogen because of the influence of 
protein conformation [12, 28] and because of its lack of high molecular mass that 
is necessary for enhanced immunogenicity. One way to solve these problems is 
to create an artificial protein by coupling the antigenic peptide to protein carriers 
such as mucosal adhering proteins. The latter include E. coli heat-labile toxin B- 
subunit (LTB) [13], and cholera toxin B-subunit (CTB). In this way, a synthetic 
immunogenic peptide is attached to part of a protein carrier capable of localizing
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in a specific tissue (mucosa of the gastrointestinal tract, for example) together 
with some other substances grafted for other purposes, especially, a reporter 
group. The functions of each of the several components can be preserved, and in 
spite of its size and complexity, the resulting product can be homogeneous, 
which is desirable for clinical use. Another way to enhance peptide 
immunogenicity is to cross-link antigenic peptides to a synthetic core in a 
branched (radial or comb) manner. For instance, Tam [14] in 1988 designed an 
amide-linked branched artificial protein, a multiple antigenic peptide (MAP) 
system, to increase molecular weight. This is a macromolecule containing 
several copies of synthetic epitopes or protein antigens that are coupled to a 
peptide core matrix (trivalent lysine) by peptide bond formation (see Figure 1). 
The polypeptide epitopes can be from the same or different immunogens. As 
MAPs are entirely synthetic, they are safe vaccines in respect to pathogens like 
human immunodeficiency or hepatitis viruses. Also, MAPs direct the immune 
system to a more specific response. More recently, it has been reported that 
MAP molecules containing 8 copies of peptide specific for sera of systemic lupus 
erythomatosus patients induced remarkable anti-DNA antibody titers and renal 
immunoglobulin deposition [15], which implies that the significant MAP 
immunogens may have potential for immuno-prophylaxis of additional infectious 
diseases. Unfortunately, with this approach it is impossible to produce 
homogeneous artificial proteins due to inevitable side-reactions and coupling 
failures, and the wanted material, when the peptide epitope is longer, cannot be 
purified from the many impurities present with similar structure.
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Figure 1: Schematic view of a multiple antigen peptide (MAP).
A rectangle ---------------------- represents for a single synthetic antigen peptide in
this thesis. Four of such polypeptides are coupled by amide bond to two lysine 
residues that are further linked to a lysine carrier. Amino acids are shown in one 
black letter code.
Over the years, site-specific conjugation, a chemical approach of ligating 
antigenic peptides to a protein or to a synthetic carrier, has been developed as a 
means of creating artificial proteins. Some mild and effective methods for N- 
terminal [16-20] or C-terminal [21-24] site-specific tagging have been described. 
One of these employs oxime chemistry that permits the modification of proteins 
without damaging their intricate structure [25]. In this way, part of a protein which 
has a desired function (an enzymatic activity, or ability to localize in tumor tissue, 
for example) is ‘cut out’ and ‘pasted’ together with some other structures which 
may themselves be proteins or may be synthetic drugs (drugs to kill tumor cells, 
for example) or may be other substances grafted for other purposes, such as 
poly(ethyleneglycol) to extend biological half-life and reduce immunogenicity, a 
fluorescent dye reporter group, a lipid to modulate immunological properties, or 
even nucleic acid for gene therapy applications. For example, the N-terminal
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threonine residue of p-lactamase may be oxidized by periodate into an aldehyde 
function group under mild conditions and then reacted with an aminooxyacetyl- 
modified murine antibody Fab’ to form a homogeneous enzyme-antibody Fab’ 
conjugate with coupling efficiencies of at least 72%. In this case, the oxidation 
reaction is rapid and quantitative but the oximation occurs very slowly. The 
resulting p-lactamase/Fab’ conjugate was used as a functional targeting agent 
[26]. Cholera Toxin B-subunit (CTB), on the other hand, is a protein that can 
induce a mucosal immune response and supply T helper epitopes. Its N- 
terminus, also threonine, can in principle undergo such oxidation and oximation 
to form conjugates with a cascade of immunogenic peptides [25,27,28].
3. Immunological mechanism
Synthetic peptide vaccines are made from antigens that can be classified as T  
cell dependent antigens (Td) or T cell independent antigens (Ti). They stimulate 
specific humoral immune responses with or without T cell help, respectively. A 
successful vaccine should be able to: (1) induce neutralizing antibody; (2) induce 
immuno-tolerance related lymphokines; (3) induce cell-mediated immunity (CMI), 
especially cytotoxic T cells (CTL), to ensure recovery from infection; (4) induce 
long-lasting memory T and B cells to ensure sustained protection. B cell 
activation and induction of antibodies are key processes involved in vaccine- 
induced humoral immune response.
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The main approaches to vaccination that have been tried are listed in Table 1. 
Among them, the goal of synthetic vaccine research is to identify the most 
immunogenic antigens or epitopes of microbial antigens, to synthesize these in 
the laboratory, and to use the synthetic antigens as vaccines. In this case, linear 
peptides can be synthesized as synthetic antigen vaccine based on the known 
sequences of microbial antigens. Sequences of the linear peptides are epitopes 
or even individual residues that are recognized by B or T cells or that bind to 
MHC (major histocompatibility complex) molecules for presentation to MHC- 
restricted T lymphocytes, and are identified by testing overlapping peptides and 
by mutational analysis. Such peptides usually are weakly immunogenic by 
themselves [29] and need to be cross-linked to a synthetic core in a branched 
(radial or comb) manner or be coupled to large proteins to induce immune 
response. This approach has the potential for creating at will vaccines with high 
potency antigenicity.
3.1 Activation of cytotoxic T cells (CTLs) [30,31]
Peptide vaccines like other foreign antigens can initiate cell-mediated immunity 
(CMI), especially through cytotoxic T cells (CTLs), to ensure recovery from 
infection by microbial or viral agents. Vaccines are first recognized by APCs 
(antigen-presenting cells) in the peripheral lymphoid organs. Occupied receptors
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are internalised and bound antigens are processed and presented on class I 
MHC molecules on the surface of APCs, which then activates the T cell receptor 
complex (TCR) of the T lymphocytes and initiates primary T cell responses. The 
activation of the naive T cells leads to proliferation of the antigen-specific clone 
and CD8+ T cells differentiate into functional CTLs, which posses the ability to kill 
infected target cells by inducing target cells to undergo programmed cell death 
(also called apoptosis).
3.2 T cell dependent B cell activation
Vaccines made from To antigens, for example, sheep red blood cells (SRBC) or 
monomeric proteins, induce B cell responses exclusively in the presence of 
specific T cell help [32]. Td antigens are recognized and processed by APCs, and 
then displayed in the form of class II MHC-associated peptides on the surface of 
APCs, which activate TCR of the helper T lymphocytes type 2 (Th2). An 
additional signal that is also required for costimulation of Th2 activation is 
provided either by a secreted chemical signal (e.g. interleukin-1, IL-1) or by the 
plasma-membrane-bound signaling molecule B7 on the surface of the APCs. The 
latter is recognized by a co-receptor, CD28, on the surface of the Th2 cell. B 
lymphocytes are activated exclusively in the presence of an antigen (signal-1) 
followed by a second signal (signal-2). The latter is believed to be provided by 
the TCR of Th2 cells [33], by costimulatory molecules (e.g. CD40 on B cells) and
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interleukins (IL-4 and IL-5) released by T cells [31]. Lack of signal-2 will lead to B 
cell tolerance instead of activation.
3.3 T cell independent B cell activation
The activation mechanism of synthetic antigen vaccines made from T| antigens is 
quite different from that of vaccines made from To antigens. These T| antigens 
are potent B cell stimulators (T| type 1, e.g. lipopolysaccharide, LPS) or repetitive 
antigens (Ti type 2, e.g. haptenized proteins, synthetic polymers). T| -1  antigens 
such as LPS can activate polyclonal B cells by binding of its antigen determinant 
to the receptor on the surface of B cell, followed by binding of its mitogen 
structure to the corresponding receptor of B cell surface, in the absence of T cell 
help or APCs. Ti -2  antigens contain repetitive determinants, which are not 
degraded in vivo. They can activate B cell by cross-linking the receptor on the 
surface of B cells, in the presence of APCs and some residual T cell help. In 
addition, Ti -2  antigens, because of their organization and repetition, may induce 
B cell intolerance. In transgenic mice expressing the membrane form of VSV-gp 
as a self antigen, Bachmann et al. found no antibody production upon 
immunization with poorly organized VSV-gp, but the tolerance was broken and B 
cell responsiveness was restored when the same mice were immunized with 
highly organized VSV-gp particles [34, 35]. This indicates that organization itself 
may be an important parameter for the immune system to discriminate self­
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antigens from non-self-antigens [36]. These results clearly have important 
consequences for the design of artificial protein vaccines.
3.4 The generation of antibody diversity [37]
Interaction of B cell receptors (BCR) with antigens leads to the activation of a 
protein kinase cascade and increased intracellular Ca2+ concentration [38]. In the 
presence or absence of T cell help, B cells proliferate and differentiate into 
antibody-forming cells. During B cell development, various antibodies are 
produced from three pools of gene segments, encoding K light chains, A light 
chains, and heavy chains, respectively. In each pool, separate gene segments 
that code for different parts of the variable regions of light and heavy chains are 
brought together by site-specific recombination. To make an antibody molecule, 
a variable region of light-chain gene segment (V|_) is recombined with a joining 
gene segment (Jl) to produce a DNA sequence coding for the V region of the 
light chain. And a variable region of heavy-chain gene segment (V h) is 
recombined with a diversity (D) and a joining (Jh) gene segment to produce a 
DNA sequence coding for the V region of the heavy chain. Each of the 
assembled gene segments is then co-transcribed with the appropriate constant 
(C) region sequence to produce an mRNA molecule that codes for the complete 
polypeptide chain. Thousands of different light chains and thousands of different 
heavy chains can be made by variously combining inherited gene segments that
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code for V|_ and Vh regions. Since the antigen-binding site is formed where V|_ 
and Vh come together in the final antibody, the light and heavy chains can pair to 
form antibodies with millions of different antigen-binding sites. This number is 
enormously increased by the loss and gain of nucleotides at the site of gene- 
segment joining, as well as by somatic mutations that occur with very high 
frequency in the assembled V-region coding sequences following antigen 
stimulation.
3.5 Mucosal immunity
Many important pathogens, including respiratory microorganism such as 
influenza viruses and enteric microorganism such as Vibrio cholerae and 
enteropathogenic Escherichia coli, initiate their infectious processes at mucosal 
surfaces. But most vaccines are given by injection, which is not the usual route of 
entry of the majority of pathogens so it can be difficult to induce mucosal 
immunization. It is therefore important to develop a new strategy by using 
mucosal vaccination to achieve more effective immunization.
The mucosal immune system is a collection of lymphocytes and accessory cells 
in the epithelia and lamina propria of mucosal surfaces such as the 
gastrointestinal and respiratory tracts, and it responds to and protects against
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microbes that enter the body through mucosal surfaces. The immune system of 
the mucosal surface is distinct in many ways from systemic ones (Table 2).
At the present time the rules of mucosal immunity are poorly understood. It is 
known that the mucosal immune system is capable of responding to and 
eliminating mucosal infections such as cholera and polio. In addition, oral or 
nasal administration of antigens usually results in inducing tolerance, and this 
ability can be explored as a therapeutic mechanism for reducing unwanted 
immune responses [39].
Table 2: Characteristics of systemic and mucosal immunization
Systemic (internal) Mucosal (external)
IgG and IgM produced IgA and IgG produced
Injectable inoculation Injection not necessary
Training required to administer Little training to administer
Systemic immunity only Local and systemic immunity
Boosts mucosal response Enhanced by parenteral priming
Responds to small amount of antigen More antigen needed to induce response
Sensitive to complex microbial antigens 
(whole cells)
Mucosal adhesin is critical property 
Common mucosal immune system
A series of bacterial toxins, such as the E. coll heat-labile toxin, cholera toxin and 
pertussis toxin which are powerfully immunogenic at mucosal surfaces, have the 
property of binding to eukaryotic cells and are protease-resistant. It has been
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found that the protein toxins from these organisms have adjuvant properties that 
are retained even when the parent molecule has been engineered to eliminate its 
toxic properties [39]. More importantly, if one vaccinates an individual by the oral 
route, the mucosal immune response is not restricted to the intestine but through 
the migration and homing of immune cells it also partly disseminates to other 
mucosal and glandular tissues (e.g. respiratory and urogenital tract) [40]. The 
ability of these proteins to stimulate immune responses is therefore of potential 
practical importance as adjuvants for oral or nasal vaccines.
4. Human Immunodeficiency Virus and vaccines for acquired 
immunodeficiency syndrome
Human Immunodeficiency Virus type-1 (HIV-1) is the main type of HIV virus 
which can cause the destruction of CD4+ lymphocytes in the host resulting in the 
development of acquired immunodeficiency syndrome (AIDS) [41, 42]. This 
pathogenesis comes from a specific interaction between CD4, the viral receptor, 
and the gp120 exterior envelope glycoprotein of host CD4 positive cells. The 
binding then initiates a cascade of intracellular events leading to the fusion of the 
viral and host cell membrane that allows viral entry [43].
Infection with HIV generates an adaptive immune response that contains the 
virus but only rarely eliminates it. In most individuals neutralizing antibodies that 
mainly target envelope glycoproteins are produced but the titers are low during
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progressive disease [44, 45]. Antibodies induced from hypervariable regions are 
type-specific [46], whereas the antibodies induced from conserved areas are 
group-specific [47]. Cellular responses are also directed against HIV-1- 
associated antigens. CTLs react with env, pol, and gag and regulatory gene 
products [48-50], and the CTL reactivity is mediated by MHC complex-restricted 
CD3+-CD8+ peripheral blood lymphocytes. Antibody-dependent cell-mediated 
cytotoxicity (ADCC) directed against HIV-1-infected cells has also been observed 
[51, 52]. This activity is initiated usually on virus-infected cells, which can express 
on their surfaces viral proteins that can be recognized by antibodies and then 
signal the presence of intracellular infection leading to the destruction of the 
antibody-coated cells by a natural killer cell (NK cell). Such activity in HIV- 
infected cells appears to reside in IgG fractions and is directed predominantly 
against exterior envelope epitopes gp120 and gp41. Non-T-effector cells also 
display phenotypic cytotoxic reactivity against HIV-1 gp120, resembling those 
with natural killer (NK) activity [53]. In addition, antibody responses to the core 
protein p24 of HIV-1 have been reported. The known immune responses to HIV 
are shown in Figure 2. It is not clear what host responses are important in 
protection against HIV-1 infection or disease, and it is also not clear whether 
such a protective response can be elicited at all. Answers to these questions are 
crucial to successful vaccine development.
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Immune response to HIV
Antibodies against HIV Env
1 i \ \  Antibodies against HIV p24
4-8 weeks 2-12 years 2-3  years ^
Figure 2. The immune response to HIV
Infectious virus is present at relative low levels in the peripheral blood of infected 
individuals during a prolonged asymptomatic phase but is replicated persistently 
in lymphoid tissues. During this period, CD4 T cell counts gradually decline, 
although antibodies and CD8 cytotoxic T cells directed against the virus remain 
at high levels. Two different antibody responses are shown in the figure, one to 
the envelope protein (env) of HIV, and one to the core protein p24. Eventually, 
the levels of antibody and HIV-specific cytotoxic T lymphocytes (CTLs) also 
decline, and there is a progressive increase of infectious HIV in the peripheral 
blood.
Table 3: Summary of the main hurdles in development of an AIDS vaccine
1. Identification of immunogens that induce broad and long-lasting CTL immunity.
2. Definition of structures and immunization strategies that elicit broadly 
neutralizing antibodies
3. Definition of immune correlates of protection in human or animal models
4. Strategies to address HIV clade and strain diversity
5. Expansion of human clinical trials:
Clinical-grade vaccine production 
Diversity and duration of immune response
Prioritization and analysis of candidates_______________________________
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The search for an effective AIDS vaccine was started over 15 years ago, but big 
challenges face laboratory and clinical research. Table 3 summarizes the main 
hurdles in the development of an HIV vaccine [54].
Firstly, a CTL response is highly desirable in an AIDS vaccine because CTLs can 
eliminate or reduce virus production by killing viral producer cells. However, a 
CTL response alone is unlikely to provide complete protection, and such a 
vaccine depending strictly on a CTL response may be countered by viral 
adaptations that allow the virus to evade detection by T cells. (For example, HIV 
can disrupt the major histocompatibility complex (MHC) proteins that T cells rely 
on to recognize foreign antigens on the cell surface [54]). Secondly, an AIDS 
vaccine to elicit neutralizing antibodies to the virus is also crucial, because such 
antibodies are dependent on memory B cells that can divide and differentiate into 
the antibody-producing cell upon re-exposure to antigen, thus conferring long­
term protection. Both of these immune mechanisms can be manipulated in 
vaccine development and each has its advantages and disadvantages (Table 4).
In this thesis we speculate on immunological properties of HIV antigens 
displaying repetitive epitopes, which could, we propose, mimic the 
conformational structure of native HIV antigens due to the peptide flexibility of the 
Multiple Antigen Peptide (MAP). We aim to investigate the effect of peptide 
multiplicity on immunogenicity using a model peptide from the envelope protein 
gp120 of Human Immunodeficiency Virus type-1 (equivalent paper A and B) [12].
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Recognition of virally infected cells 
Multiple linear epitopes 
Elimination of virus production 
Possible effect on latent reservoir
Disadvantages
Requirement for active, long-term 
memory cells
Inability to recognize virus in 
absence of MHC




Ability to prevent new infection of 
cells
Activation of inflammatory 
response (complement system, 
neutrophiles and monocytes)
Inability to generate broadly 
neutralizing antibodies
Evolution of resistant strains
Antibodies may enhance 




Induction of cell-mediated and 
humoral immunity
Interference
Safety and inadvertent infection
Enhanced replication during 
immune suppression
Consequences of persistent 
immune stimulation
Increased rates of integration
5. Cholera Toxin and its B Subunit as vaccine carriers
Cholera toxin (CT) is the primary enterotoxin produced by Vibrio choierae 
bacteria, and is the causative agents of cholera infection. This is an AB5 
hexameric protein, 5 identical B subunits and a single A subunit. Cholera toxin A 
(CTA) subunit is responsible for severe fluid loss and diarrhea of infected host. 
Cholera toxin B subunit (CTB) is the nontoxic binding subunit of the CT holotoxin
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[55] and it functions in a pentameric-form which can specifically recognize the 
GM1 ganglioside receptor present on the surface of mucous cells. Oral 
administration of CTB can produce a protective intestinal secretory response
[56].
CTB was at first developed as an oral vaccine against cholera [57, 58]. This 
vaccine contains a mixture of B subunit and killed V. cholerae 01 cells, and 
studies showed that it is completely safe as well as strongly immunogenic and 
protective. Table 5 lists the functional properties of the oral cholera vaccines.
Table 5: Functional properties of the oral B subunit-01 whole cell cholera vaccine
Safe No adverse reactions
Immunogenic Strong intestinal IgA immunogenicity (comparable to clinical disease)
Protective Cholera
85% protection first 6 months 
60% first 3 years
CTB is a potential carrier of mucosal vaccines. It is known that CTB, when 
conjugated to a poor immunogen and given orally, dramatically increases 
mucosal immunogenicity [59, 60]. And CTB can supply a universal T helper 
epitope, which then increases the systemic immunity of vaccines. Fusion of CTB 
to a proteolipid-protein peptide could induce an inhibition of the specific response
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of the peptide [61]. Holmgren, J. et al and other workers also showed that the 
physical coupling of foreign antigens to CTB is a very effective way of inducing 
such mucosal immune response after oral vaccination [62]. In addition, Rose’s 
group, including Chen J., also reported that the N-terminus of CTB, a threonine, 
could in principle undergo oxidation and oximation to form conjugates with a 
cascade of immunogenic peptides [28]. This also offers a possible way to 
generate novel mucosal vaccines that possess chemically coupled peptides and 
are reconstituted into a CT-like complex in vitro. Since the mucosal immune 
response from oral vaccination is not restricted to the intestine but also partly 
disseminates to other mucosal tissues, it then gives prospect to use CTB as a 
vaccine carrier against infections in the intestinal as well as in any other mucosal 
tissues.
In this manuscript we set up a model of CTB by engineering a peptide derived 
from hemaglutinin protein of influenza virus to the N-terminus (equivalent paper 
C). W e wish to use this model to study the effect of attaching a cascade of 
immunogenic peptides to CTB (equivalent paper D).
6. Artificial Proteins as Targetting Moieties
Recent progress in biology has greatly benefitted from the understanding of 
molecular interactions such as binding activities between various receptors on
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the cell surface and their specific ligands. This binding causes a conformational 
change in the receptor that initiates a cascade of intracellular events leading to a 
specific cellular response. The research on binding effects of the ligand and its 
specific receptor is an important means to study many biological activities 
including the growth, differentiation, and metabolism of the multitude of cells.
In the study of binding activities, the peptide ligands are often identified using a 
powerful technique "phage display random peptide library”. As these peptides do 
not represent the natural ligand of the receptor but rather mimic it, they are called 
mimitopes which can either be displayed as a linear or, if flanked by two cysteine 
residues, as a circular peptide, and the latter may also mimic conformational 
structure. Briefly, a DNA fragment expressing the ligands is first inserted into a 
minor coat protein gene of filamentous phage creating a fusion protein that is 
incorporated into the virion (named "fusion phage”). The fusion phage that 
displays billions of different short peptides is then screened for tight binding to a 
receptor or antibody [63, 64]. The selected peptides can be reproduced as a 
synthetic or recombinant peptide outside the context of the phage particle.
However, the obtained ligands are usually of low-affinity (micromolar range). [65, 
66] This may be due to the high degree of conformational freedom and small 
number of contact residues within a short peptide molecule. But, if several copies 
of the peptide molecule with low-affinity binding sites are present in a single 
multimeric molecule, avidities (and bioactivities) can be greatly enhanced over
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the affinity or activity of monomeric peptide. In nature, there are many examples 
of molecules with low-affinity binding sites, yet capable of high avidity interactions 
with their targets due to multivalent binding. For example, IgM produced during 
the primary immune response is pentameric and this confers high avidity toward 
repetitive antigenic determinants present on the surface of bacteria or viruses
[67]. Such enhancement (105-fold) occurred with the peptabody (see Figure 3)
[68], a protein produced through recombinant DNA techniques. In this protein, 
the low affinity of polypeptide derived from phage library is compensated by its 
pentameric structure resulting in a high avidity toward their targets. Recently, 
Rose K [69] also designed such a molecule named as "chemobody” (see Figure 
4). This is a synthetic molecule displaying multiple copies (at least two) of a 
peptide subunit capable of binding non-covalently to a complementary structure, 
thus mimicking a major feature of the antibody molecule. The amino acid 
sequence of the binding peptide was identified using phage library techniques 
and the subunits themselves were assembled using oxime chemistry. To be able 
to bind through two or more subunits simultaneously, an appropriate spacer 
polyethyleneglycol (PEG) chain and a linker were also introduced, which are 
flexible, amphiphilic, non-immunogenic, and unsusceptible to proteases. And 
some reporter group such as FITC (fluorescein isothiocyanate) or Biotin can also 
be introduced into the linker moiety of the Chemobody much more easily than 
into the Peptabody. Thus the Chemobody possesses more flexibility and it is 
more convenient for biological use.
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Figure 3: Space-filling (Left) and ribbon (Right) representations of a model of the 
three-dimensional structure of Pab-S. Binding peptides are in red. The upper part 
of the structure shows six histidine residues at each C terminus. One chain within 
the pentameric molecule is highlighted in blue in the space-filling representation. 
Five shaded circles (radius of 40 A) under the ribbon structure schematically 
denote receptor molecules. The ribbon representation was generated with the 
program MOLSCRIPT.
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Figure 4: Profile of structure of a tetrameric chemobody
Structure of a tetrameric chemobody displaying four copies of the phage derived 
peptide SVWRWLPYDKYE. Flu, acetaminofluorescein; Cy, cysteamine linker; 
ox, oxime linker; s, -COCH2CH2CO-; p, -NH-CH2CH2CH2-(OCH2 CH2)3-CH2-NH-.
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We have created in our laboratory a model chemobody [69] that displayed 2 or 4 
copies of synthetic erythropoietin mimetic peptide together with flexible 
polyethyleneglycol (PEG) linkers. In this manuscript, we wish to apply this 
strategy to design and synthesize a set of multimeric molecules that display 
binding peptides to insulin-secreting cells, and to exploit the enhanced avidity 
through multivalent binding.
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Summary
A multiple antigen peptide (MAP) system consisting of antigenic peptides linked 
by amide bonds to a synthetic core can elicit enhanced immunogenecity. 
However, it is difficult to prepare MAPs possessing long polypeptide chains in 
homogeneous form. We describe the synthesis of octa-branched MAPs using 
direct Boc-chemistry. Using a peptide from HIV-1, three different MAP constructs 
were made by stopping the synthesis at different stages. Warming the reaction 
mixture was essential for three critical couplings. The MAP with the shortest 
peptide sequence was characterized by MALDI-TOF mass spectrometry. Edman 
degradation of the MAPs possessing intermediate and full-length peptides 
showed that the correct sequence was present but it was not possible to obtain a 
mass spectrum by MALDI or electrospray technique. An octaoxime was made by 
site-specific conjugation of 8 pre-purified peptides to a synthetic radial polylysine 
core. Results showed that it was homogeneous on RP-HPLC and 
characterizable by ESI-MS. Attempts to use thioether chemistry failed, producing 
up to a 7-branched product but no octamer. Factors influencing the syntheses of 
MAPs, oximes and thioether constructs are discussed.
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Introduction
Synthetic peptides can induce antibodies that are useful in vaccination strategies 
or as laboratory reagents, for example, in the study of biosynthetic pathways by 
confirming de novo synthesis of proteins from recombinant DNA [1], However, a 
small linear peptide may not be effective as an immunogen because of the 
influence of protein conformation [2] or because of its lack of high molecular 
mass that appears necessary for enhanced immunogenicity. One way to 
enhance peptide immunogenicity is to attach antigenic peptides to a synthetic 
core in a branched (radial or comb) manner. Tam [3] in 1988 described an 
amide-linked branched artificial protein to increase molecular weight. In this 
approach a trifunctional amino acid, Boc-Lys(Boc), is used to create a multiple 
antigenic peptide (MAP) system. Many useful results have been obtained with 
this approach but, unfortunately, it is rather difficult to produce homogeneous 
artificial proteins with many (e.g. 8) branch points and long polypeptides due to 
inevitable side-reactions and coupling failures. It is difficult to purify the wanted 
material from the many impurities present with similar structure and physico­
chemical properties.
Over the years, site-specific conjugation, an effective chemical approach of 
ligating antigenic peptides to a protein or a synthetic carrier under mild conditions 
[4-12], has been developed as a means of creating artificial proteins. For 
example, N-terminal Serine residues in an octavalent core can be oxidized by 
periodate into aldehyde functional groups under mild conditions, and then 
aminooxyacetyl polypeptides can be reacted with each aldehyde group to give a 
homogeneous octaoxime [13]. An alternative chemoselective ligation method 
involves thioether chemistry [14-15]. While disulphide formation and non-specific 
alkylations are possible side-reactions, some useful immunogens have been 
made by the thioether approach.
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Human Immunodefienciency Virus type-1 (HIV-1) is the main type of HIV virus 
which can cause the destruction of CD4+ lymphocytes in the host resulting in the 
development of acquired immunodeficiency syndrome (AIDS) [16-17]. gp120 is 
the envelope glycoprotein spiked on the virion surface which mediates HIV entry 
into the target cell, a critical step of its pathogenesis. In previous work, a peptide 
was synthesized by mimicking certain epitope residues (419-439) of gp120, 
which was expected to induce an antibody to disrupt the entry of HIV, thus 
interfering with its pathogenesis [18]. However, the antibody induced by peptide 
monomer was found not to recognize the native conformation of gp120. 
Surprisingly, an octamer synthesized directly as an amide-linked MAP was able 
to induce the desired neutralizing antibodies, but the preparation was 
heterogeneous and unpurifiable, being the result of over two hundred coupling 
reactions.
In this article we compare the syntheses of octa-branched immunogens, based 
on the gp120 (419-439) peptide, using three approaches: direct amide bond 
formation, and chemo-selective ligation involving either thioether or oxime 
chemistry.
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Methods
Materials
Unless otherwise specified, all solvents and reagents were obtained from Fluka, 
Buchs, Switzerland, were of analytical or higher grade and were used without 
further purification. All amino acids were purchased from Peptide Institute Inc. 
Japan. Resins were from Applied Biosystems, USA; Novabiochem, Switzerland, 
or Bachem, Switzerland. Water was repurified using a Milli-Q system (Millipore, 
Inc.).
RP-HPLC
Analytical RP-HPLC was performed using a column 250 x 4 mm i.d. packed with 
Nucleosil 300-A 5 pm Cs particles at a flow rate of 0.6 ml/min and effluent was 
monitored at 214nm. Semi-preparative peptide purification was carried out using 
a Cs column (250 x 10 mm i.d. Nucleosil 300-A 5 pm particle size) at a flow rate 
of 4 ml/min monitoring at 214 nm, and preparative purification using a Cis column 
(210 x 25 mm i.d. Novapak 6 pm particle size) at 20 ml/min monitoring at 229 
nm. Solvents used in RP-HPLC were as follows: A, 0.1% TFA (1 g TFA in 1 liter 
H20); B, 0.1% TFA in 90% acetonitrile (1 g TFA mixed with 100 ml H20  and then 
brought to1 liter with acetonitrile). Generally, the conditions used in the analytical 
work were 5 min isocratic at 100% A followed by a linear gradient 2% B/min to 
100% B, and in the preparative work a shallower linear gradient (usually 0.5%  
B/min ) was used. Components were collected manually at the detector exit, 
evaporated at room temperature, frozen and then recovered by lyophilization.
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Mass Spectrometry
Electrospray ionization mass spectrometry (ESI-MS) was performed in positive 
ion mode on a Trio 2000 machine or a Platform II instrument (both from 
Micromass, Manchester, England). Samples were introduced either at 2 pl/min 
(Trio) in an acidified solvent acetonitrile/water/AcOH (49.5 : 49.5 : 1) or at 10 
pl/min (Platform) in solvent acetonitrile/water/formic acid (49.9 : 49.9 : 0.2). 
MALDI-TOF mass spectrometry was performed in linear mode using sinapinic 
acid as matrix on a Voyager Elite machine (PE Biosystems) equipped with 
delayed extraction. External calibration was performed on the electrospray 
machines by using a solution of horse heart apomyoglobin, and on the MALDI- 
TOF machine using the mixture of peptides supplied by the manufacturer.
Protein sequencing
Unpurifiable MAP-2 and MAP-3 were sent to Eurosequence (Nijenborgh 4 -  NL 
9747 AG Groningen -  The Netherlands) for protein sequence analysis by Edman 
degradation.
Syntheses of MAP constructs
Three MAP (multiple antigenic peptide) constructs were designed as before [18], 




They were synthesized stepwise on Boc-pAla-PAM resin using Boc-chemistry. 
The syntheses were monitored by ninhydrin test, and re-couplings were
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performed on some amino acid residues in order to achieve apparently 
quantitative acylation. Three amino acid residues, Tyr(435), Glu(429), and 
Arg(419) required heating to between 40°C-60°C to couple quantitatively as 
monitored by the ninhydrin test. All of the MAP products were cleaved from the 
resin with HF, purified by semi-preparative HPLC and characterized by MALDI- 
TOF mass spectrometry.
Syntheses of a polylysine core and linear peptides
The core structure used in the project was SsK^K-pA-OH. Synthesis was 
performed manually on 0.2 mmol of Boc-pAla-PAM resin (substitution 0.88 
mmol/g) using Boc-chemistry. Three cycles of Boc deprotection and couplings of 
Boc-Lys(Boc) formed the polylysine core and were followed by attachment of 
Boc-Ser(Bzl) to the branched core with 8 mmol Boc-Ser(Bzl)-OSu in 8 ml DMSO 
and 2 ml N-methylmorpholine.
The antigenic peptide sequence RIKQIINMWQEVGKAMYAPPIGGGK' from 
gp120 envelope protein of HIV-1 [18] was synthesized by Boc chemistry on 
methylbenzhydrylamine resin (0.2 mmol MBHA resin, PE ABI division) using an 
automated solid-phase synthesizer (model ABI 430A, Applied Biosystems Inc.). 
Italic type denotes linker residues not present in the corresponding protein 
sequences. Side-chain protection was Arg(Tos), Asn(xan), Trp(CHO), 
Glu(OcHx), Tyr(2-BrZ), Lys(CIZ), C-terminal Lys(Fmoc). After chain elongation by 
Boc chemistry, side-chain protection (Fmoc) at the C-terminal Lys was removed 
with 20% piperidine in DMF. At this stage, an aminooxyacetyl (AOA) group was 
attached to the Lys residue with Boc-AOA-Osu (5-fold excess over the 
substitution of the resin in 5 ml DMSO, 1 ml N-methylmorpholine) to form an 
HIV1-derived aminooxyacetyl peptide.
All of the peptides were cleaved from the resin with HF (0°C for 1 h in the 
presence of 5% p-cresol), precipitated with cold ether, extracted with 50%
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acetonitrile, filtered and lyophilized. The crude peptides were purified by 
preparative HPLC and characterized by ESI-MS.
Periodate oxidation
3.75 pmol of core was dissolved in 23.5 ml imidazole buffer (50 mM, pH 6.95, 
chloride counter ion) and 1.3 ml of methionine (200 mM) was added. Then 625 pi 
of Nal04 (0.2 M in water) was added to start the oxidation. After 5 min the 
reaction was quenched by adding 500 pi of ethylene glycol (500 mM in water). 
The product was purified by preparative HPLC and characterized by mass 
spectrometry.
Oximation
The aldehyde obtained by oxidation was reacted with the HIV-1 derived 
aminooxyacetyl peptide, H-RIKQIINMWQEVGKAMYAPPIGGGKfCOCHaONH^- 
NH2 to form an octa-oxime (see Figure 1). 4.8 pmol of aminooxyacetyl peptide 
was dissolved in about 50 pi of acetonitrile and 1.2 ml of NaOAc buffer (acetic 
acid 0.57 ml in 100 ml of water, sodium acetate 0.82 g dissolved in 100 ml of 
water, mixed part of both until pH 4.0). 0.3 pmol of oxidized core was dissolved in 
100 pi NaOAc buffer and added to the above solution, followed by addition of 
acetic acid to a final concentration of 4%. After 24 h reaction at room 
temperature, the product was purified by semi-preparative RP-HPLC and 
characterized by mass spectrometry.
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Characterization of MAP constructs of HIV-1
A MAP (multiple antigenic peptide) construct with 8 identical peptides (residues 
419-439, RIKQIINMWQEVGKAMYAPPI, from the gp120 glycoprotein of HIV-1) 
was able to induce antibodies recognizing conformational determinants on the 
gp120 envelope protein which were not recognized by the antibodies induced by 
monomer envelope-derived peptide [18]. The MAP constructs were referred to as 
MCP (multiple chain peptides) in that paper but we will use the more 
conventional term here. We repeated the synthesis of the MAP construct using 
an octavalent branched lysine core, and removed aliquots of resin at 3 different 
stages: Val(430), lle(424) and Arg(419). Three different MAP constructs were 
thus obtained: with 8 identical short-length peptides VGKAMYAPPI (MAP-1), with 
8 identical medium-length peptides INMWQEVGKAMYAPPI (MAP-2), and with 8 
identical full-length peptides RIKQIINMWQEVGKAMYAPPI (MAP-3). During the 
synthesis, some amino acid residues such as Tyr(435), Glu(429), and Arg(419) 
were found difficult to couple at room temperature even after multiple attempts, 
even with very activated coupling species, and had to be warmed to 40 degrees 
or even 50-60 degrees. The peptide resins were cleaved and the crude products 
purified on semi-preparative-HPLC. MAP-1 (see figure 2) was successfully 
characterized by MALDI-TOF mass spectrometry (M + H® found 10587, 
calculated 10581), but MAP-2 and MAP-3 (see figure 2) failed to give 
interpretable spectra which was consistent with previous work [17]. Results of 7 
cycles of Edman degradation of MAP-2 and MAP-3 showed that the expected 
amino acid sequence was present. Initial yields of the main sequence were 
approximately 50 pmol for MAP-2, 100 pmol for MAP-3: MAP-2, lle-Asn-Met-Trp- 
Gln-Glu-Val; MAP-3, Arg-lle-Lys-Gln-lle-lle-Asn. Initial yields of minor sequences: 
(approximately 1 -  5 pmol for both) were: MAP-2, (lle?/Thr?)-(Pro/Met)-(Gln/Trp)- 
(Gln/Phe/Glu?)-/Gly/Ala/Val)-(Val/Gly/Leu)-(Lys/Gly); MAP-3, (lle)-(Lys/Pro/Gln)-
Chen J. Page 46 Equivalent A
(Gln)-(lle)-Asn)-(Asn/Met)-(Met/Asp). The failure to produce homogeneous 
synthetic MAP-2 and MAP-3 constructs led us to explore alternative strategies for 
the synthesis of an octameric immunogen.
Thioether constructs
In order to obtain homogeneous multimeric immunogens, we employed site- 
specific conjugation, by which pre-purified peptides can be ligated to a synthetic 
polylysine core. We investigated alkylation of a bromoacetylated core with a C- 
terminal Cys peptide. While the reaction was very clean when analyzed by 
HPLC, Mass Spectrum showed that only seven peptides became attached to the 
octa-bromoacetyl core in spite of many attempts with large excesses of Cys 
peptide.
Polyoxime constructs of HIV-1 gp120 (419-439)
Oxime formation requires an aminoxyacetyl group and a carbonyl group, 
generally an aldehyde [7]. The latter is easily generated from N-terminal or side 
chain-linked Ser, Thr, or carbohydrates [6, 7, 19], and can then react with the 
aminooxyacetyl-containing species.
Oxime bond formation involves the specific reaction between an aminooxy group 
and a carbonyl group (aldehyde or ketone) and explusion of a water molecule in 
aqueous medium under acidic conditions. Oximation is very slow at neutral pH 
but proceeds close to completion at acidic pH over a period of hours [13]. Using 
oxime chemistry, it was possible to assemble multimeric constructs that 
possessed eight copies of the HIV1-derived peptide described by Kelker et al
[18]. Because the peptide subunit was purified and characterized prior to 
assembly, it was possible to characterize the final product by mass spectrometry.
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The octameric construct was built on a radial polylysine core containing a Ser 
residue at the tip of each of 8 branches. Eight Ser residues were periodate- 
oxidized and then reacted with HIV1-derived peptide in aminooxy form to yield 
the octaoxime shown in Figure 1. The octaoxime was purified on reverse phase 
HPLC and characterized by ESI-MS (Figure 3). Relative molecular mass found 
24156, theoretical 24157. Some evidence was found of components with higher 
masses [+73, +156, +(156+73)]. These components, which coeluted on HPLC 
with the desired product, were probably due to acylation of the Boc-NHOCH2CO- 
nitrogen with a second Boc-NHOCH2CO- group during synthesis of the HIV1 
peptide (calculation, +73 for NH2OCH2CO replacing H) and of incomplete 
removal of the tosyl group (calculation, +154). We now use less strong acylation 
conditions (1 equivalent instead of five) which avoid the +73 problem.
Comparison of syntheses of MAPs and Octaoxime
The syntheses of MAP constructs were difficult and the products were 
heterogeneous. This is inevitable since over 200 reactions were involved without 
the opportunity to purify any intermediates. It is rather difficult to purify the final 
product from the many impurities present with similar properties. Warming to 40- 
60 degrees when coupling difficulties were encountered dramatically improved 
the synthesis. Indeed, when coupling Tyr435, Glu429 and Arg419, warming was 
essential. The standard Kaiser ninhydrin test involves heating, and we found 
through use of this test that coupling of these three residues did not occur at 
room temperature and did not improve upon repeated attempts using HBTU, 
HATU or BOP activation protocols and extended coupling times at room 
temperature (22°C). Warming the coupling reactions to 60°C, 60°C and 40°C, 
residues 435, 429 and 419, respectively, led to quantitative coupling within 30 
minutes as determined by ninhydrin reaction at 100°C. Warming is thus a simple 
and effective method to improve the synthesis of MAPs, but if repeated too many 
may lead to racemization or to degradation of the product [20].
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Octaoxime was built up by conjugation of pre-purified HIV-1 derived 
aminooxyacetyl-peptides to the radial octalysine core possesing a carbonyl group 
at the tip of 8 branches. Octaoxime is thus comparable in structure with MAP-3. 
But, in contrast with the MAP octamers, octaoxime can be prepared in 
characterizable form because there are only 8 coupling reactions involved in the 
conjugation and any coupling failures lead to materials which lack 1 or 2 whole 
peptides and are thus easily separable by RP-HPLC. A comparison between 
MAPs and Octaoxime is shown in the table.
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Conclusion
Three MAP constructs and an octaoxime were obtained by using improved Boc- 
chemistry and oxime site-specific conjugation, respectively, with a model peptide 
derived from HIV-1. Only the MAP with a short peptide sequences could be 
characterized by mass sepectrometry. MAPs with intermediate and full-length 
peptides were characterized by Edman degradation. Warming to 40-60 degrees 
when coupling critical residues improved the synthesis. It was not possible to 
prepare an octameric construct using thioether chemistry: the maximum number 
of peptide chains that became attached to the core was seven. An octaoxime 
was prepared by site-specific conjugation of 8 identical peptides to a synthetic 
radial octalysine core and was characterized by mass spectrometry. The 
octaMAP constructs and the octaoxime are being tested as immunogens in mice.
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Figure Legends
Figure 1. Reaction scheme showing periodate oxidation of radial-branched 
octaaldehyde and oxime formation with aminooxyacetyl-peptide, 
RIKQIINMWQEVGKAMYAPPIGGGK(AOA)-amide, from HIV-1 gp120. The 
branching Lys residues of the core are acylated on both alpha and epsilon amino 
groups and are shown (together with pAla and Ser residues) unconventionally 
with their carboxyl groups to the left.
Figure 2. (A) MALDI Mass spectrum of the MAP-1: (VGKAMYAPPIGGG)8k4k2ka- 
OH (calculated 10581, found: 10587); (B) Protein sequence analyses of MAP-2: 
(INMWQEVGKAMYAPPIGGG)8k4k2ka-OH and MAP-3:
(RIKQIINMWQEVGKAMYAPPI GGG)8k4k2ka-OH.
Figure 3. Electrospray ionization mass spectrum of the Octaoxime constructed 
on a radial core (calculate mass, 24157, found, 24156), see Figure 1 for 
structure.
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Table: Comparison between OctaMAPs and Octaoxime
OctaMAPs Octaoxime
Synthesis Required warming Room temperature
Reaction
mixture










None characterizale by ESI- 
MS, MAP-1 characterized by 
MALDI-TOF, MAP-2 and MAP- 
3 uncharacterizale by MS
Characterized by ESl-MS
Solubility Soluble in water Soluble in a drop of CH3CN 
+ water + 5% acetic acid
Stability Relative stable (amide bonds) Stable in solution at pH 2.1- 
7.0, room temperature for 
>65h, and in powder at -20gC 
for a long period
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(A) M A P -1
(B)
MAP-2 MAP-3
Main Sequence Main Sequence
Position 1 5 7 Position 1 5 7
Amino Acid lle-Asn-Met-Trp-Gln-Glu-Val Amino Acid Arg-lle-Lys-Gln-lle-lle-Asn
Initial Yield: appr. 50 pmol Initial Yield: appr. 100 pmol
Minor Signals Minor Signal
Position 1 Position 1 5 7
Amino Acid: (Asn ?/Thr ?)-(Pro/Met)-(Gln/Trp)-(Gln/Phe/Glu ?)- ' Amino Acid: (lle)-(Lys/Pro/Gln)-(Gln)-(lle)-(Asn)-(Asn/Met)-(Met/Asp)
5 7 Initial Yield: appr. 1-5 pmol
(Gly/Ala/Val)-(Va!/Gly/Leu)-(Lys/Gly)
Initial Yield: appr. 1-5 pmol
Figure 2
Calculated Mass : 10581 
Experimental Mass ; 10586
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Summary
An octamer MAP (multiple antigen peptide) consisting of HIV-1 gp120-derived 
peptides linked by amide bonds to a synthetic core is known to elicit enhanced 
immunogenecity to native gp120. However, it was heterogeneous and could not 
be characterized by mass spectrometry. In this study we prepared a set of 
multimeric constructs (comb-design and tree-design) employing HIV1-derived 
peptides as building blocks through oxime chemistry. They were tested for their 
antigenicity and immunogenicity in mice. Antibodies elicited by three polyoximes 
(the octa- and tetra-oxime comb and tetraoxime tree configuration) are capable 
of recognizing the native envelope protein gp120 of the virus, whereas antibodies 
raised against the monomeric peptide and other polyoximes cannot. Our results 
indicate that model octameric constructions from gp120 of HIV-1 can be made in 
pure form in good yield using oxime chemistry but not by direct synthesis as a 
MAP, and that our model constructs increase the immunogenicity.
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Introduction
HIV-1 is the main type of HIV virus which can cause the destruction of CD4+ 
lymphocytes in the host resulting in the development of acquired 
immunodeficiency syndrome (AIDS) [1, 2]. Many efforts have been made to 
search for an effective AIDS vaccine over the last 15 years, some are on-going, 
and for example, live, attenuated viruses and DNA vaccines are being tested in 
animal models. But big challenges still face this area of laboratory and clinical 
research.
Synthetic peptides are known to act as immunogens [3-6]. By mimicking certain 
epitope residues (419-439) of gp120, the envelope glycoprotein spiked on the 
virion surface which mediates HIV entry into cells, a peptide might induce an 
antibody that can be expected to disrupt the entry of HIV, thus interfering with its 
pathogenesis [7-12]. However, antibodies induced by the peptide monomer were 
found not to recognize the native conformation of gp120. This may be because of 
the influence of protein conformation [7] and because of its lack of high molecular 
mass that is necessary for enhanced immunogenicity. One way to solve these 
problems is to cross-link antigenic peptides to a synthetic core in a branched 
manner as Tam [13] described, whereby multiple copies of antigenic peptides are 
amide-linked to a lysine based core to create a multiple antigen peptide (MAP) 
system. An octamer made using this strategy and employing epitope residues 
(419-439) of gp120 was able to induce the desired neutralizing antibodies, where 
the octamer was also referred to as Multiple Chain Peptides (MCP) [7]. 
Unfortunately, the preparation was inhomogeneous and unpurifiable, being the 
result of over a hundred coupling reactions.
Over the years, site-specific conjugation, a chemical approach of ligating 
antigenic peptides to a protein or to a synthetic carrier, has been developed as a 
means of creating artificial proteins. One such method employs oxime chemistry
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that permits the mild and effective modification of proteins without damaging their 
intricate structure [14]. In this way, multiple copies of pre-pruified immunogenic 
peptides can be linked to a polylysine core in pure form in good yield, thus 
providing homogeneous materials for clinic use.
In this article, we describe the construction a series of tetra- and octamers of 
either radial or comb design to investigate the effect of peptide multiplicity on 
immunogenicity using a modei peptide from the envelope protein gp120 of HIV 
type-1.
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Materials and Methods
1. Materials
Unless otherwise specified, all solvents and reagents were obtained from Fluka, 
Buchs, Switzerland, were of analytical or higher grade and were used without 
further purification. All amino acids were purchased from Peptide Institute Inc., 
Japan. The resins were from Applied Biosystems, USA; Novabiochem, 
Switzerland, or Bachem, Switzerland. Water was repurified using a Milli-Q 
system (Millipore, Inc.).
2. R P -H P L C
Analytical RP-HPLC was performed using a column 250 x 4 mm i.d. packed with 
Nucleosil 300-A 5 pm Cs particles at a flow rate of 0.6 ml/min and effluent was 
monitored at 214nm. Semi-preparative peptide purification was carried out using 
a Cs column (250 x 10 mm i.d. Nucleosil 300-A 5 pm particle size) at a flow rate 
of 4 ml/min monitoring at 214 nm, and preparative purification using a Cis column 
(210 x 25 mm i.d. Novapak 6 pm particle size) at 20 ml/min monitoring at 229 
nm. Solvents used in RP-HPLC were as follows: A, 0.1% TFA (1 g TFA in 1 litre 
H20); B, 0.1% TFA in 90% acetonitrile (1 g TFA mixed with 100 ml H20  and then 
brought to1 litre with acetonitrile). Generally, the conditions used in analytical 
work were 5 min isocratic at 100% A followed by a linear gradient 2% B/min to 
100% B, and in preparative work a shallower linear gradient (usually 0.5% B/min) 
was used. Components were collected manually at the detector exit, partially 
evaporated at room temperature, frozen and then recovered by lyophilization.
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3. Mass Spectrometry
Electrospray ionization mass spectrometry (ESI-MS) was performed in positive 
ion mode on a Trio 2000 machine or a Platform II instrument (both from 
Micromass, Manchester, England). Samples were introduced either at 2 pl/min 
(Trio) in an acidified solvent acetonitrile/water/AcOH (49.5 : 49.5 : 1) or at 10 
pl/min (Platform) in solvent acetonitrile/water/formic acid (49.9 : 49.9 : 0.2). 
MALDI-TOF mass spectrometry was performed in linear mode using sinapinic 
acid as matrix on a Voyager Elite machine (Perkin Elmer) equipped with delayed 
extraction. External calibration was performed on the electrospray machines 
using a solution of horse heart apomyoglobin, and on the MALDI-TOF machine 
using the mixture of peptides supplied by the manufacturer.
4. Synthesis of linear peptides
The antigenic peptide sequences from gp120 envelope protein of HIV-1 [12] 
appear in Table 1.
Italic type denotes linker residues not present in the corresponding protein 
sequences. Side-chain protection of Boc-protected amino acid on HIV-1 peptide 
was Arg(Tos), Asn(xan), Trp(CHO), Glu(OcHx), Tyr(BrZ), Lys(2-CIZ), C-terminal 
Lys(Fmoc), C-terminal Cys(4-MeBzl). All the syntheses were performed using 
Boc chemistry on 0.4 mmol of methylbenzhydrylamine resin (MBHA resin, Perkin 
Elmer ABI division) using an automated solid-phase synthesizer (model ABI 
430A, Applied Biosystems Inc.). For peptides 1, 3 and 4, the Fmoc group at the 
C-terminal Lys was removed with 20% piperidine in DMF. Boc-aminooxyacetyl 
(AOA) was attached to the Lys residue with an activated mixture solution (Boc- 
AOA-OSu, 5-fold excess over the substitution of the resin in 5 ml DMSO, 1 ml N- 
methylmorpholine) to form aminooxyacetyl HIV1 -derived peptide. On peptides 3 
and 4, Boc-AOA group was attached to the C-terminal as above. The resin and 
all other side-protection groups were cleaved with HF (0°C for 1 h in the
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presence of 5% p-cresol). The peptides were precipitated with cold ether, 
extracted with 50% acetonitrile, filtered and lyophilized. The crude peptides were 
purified by preparative HPLC and characterized by ESI-MS.
5. Synthesis of core structures
The core structures used in the project are shown in Table 2.
The synthesis of cores 1 and 2 were started with Fmoc-Lys(Boc) and Fmoc- 
Lys(Mtt), respectively, on 0.2 mmol MBHA resin (substitution, 0.63 mmol/g). On 
core 1, two cycles of Fmoc deprotection (20% piperidine in DMF) and couplings 
(TBTU/HOBt/DlEA activation) with Fmoc-Lys(Fmoc) were then performed to 
provide the polylysine core structure. The side-chain protection of C-terminal Lys 
was removed by TFA, and a Boc-AOA group was attached to the Lys residue as 
above. On core 2, Boc-Ser(Bzl) was attached as above to the free amino group 
formed upon deprotection of the Fmoc group of Fmoc-Lys(Mtt) residue on the 
resin. The protecting group Mtt was removed with 1%TFA in DCM, followed by a 
coupling of a succinic group. This group was activated by CDI (carbonyl 
diimidazole) solution, and a PEG-based diamine 
NH2CH2CH2CH2(OCH2CH2)3CH2NH2 was attached with a solution consisting of 4 
ml ‘PEG’ in 2 ml DMF and 2 ml HOBt (0.5 M). Then two cycles of Fmoc- 
Lys(Fmoc) were coupled to the free amino group of the PEG to form the 
polylysine core as above. Finally, Fmoc protection was removed from the 
branches of the cores 1 and 2, and bromoacetyl groups were attached to the 
branched core with an activated mixture solution (2 mmol of bromoacetic acid in 
2 ml DCM and 1 mmol of DIC).
The syntheses of cores 3 and 4 were performed manually on 0.2 mmol Boc-pAla- 
PAM resin (substitution 0.88 mmol/g) using Boc-chemistry. Three cycles of Boc 
deprotection and couplings of Boc-Lys(Boc) formed the polylysine core. At this 
stage, three cycles of Boc-deprotection and couplings of Boc-Gly were performed
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on core 4. Boc-Ser(Bzl) was then attached to both branched cores with an 
activated mixture solution (8 mmol Boc-Ser(Bzl)-OSu in 8 ml DMSO and 2 ml N- 
methylmorpholine).
Cores 5 and 6 were synthesized manually on 0.2 mmol Boc-Gly-PAM resin. After 
Boc deprotection, 7 and 3 cycles, respectively, of coupling with Fmoc-Lys(Boc) 
and deprotection were performed by Fmoc-chemistry to form the linear polylysine 
core, followed by two cycles of Fmoc-Gly. A Boc-Gly was attached after Fmoc 
deprotection of the last cycle. The side chain protection of Lys core and 
protection of N-terminal Gly were removed with TFA, and Boc-Ser(Bzl) was 
attached as for core 3.
Core 7 was synthesized similarly to core 5 on 0.2 mmol Boc-Gly-PAM resin, but 
Fmoc-Lys(Mtt) instead of Fmoc-Lys(Boc) was used in the 4th cycle. After the 
coupling cycle of Boc-Gly, the Mtt group was removed with 1% TFA in DCM 
through the reaction column and the removal was spectrophotometrically 
monitored at 470 nm, followed by attachment of Fmoc-Ser(Bzl)-OH to the side 
chain of 4th Lys by using Fmoc chemistry. Boc deprotection was performed on 
the side chain of the rest of the Lys residues and on the N-terminal Gly, and then 
the amino groups were acetylated for 1 hour with acetic anhydride (14 mmol) and 
DIEA (28 mmol). Fmoc group on the Ser residue was removed prior to final 
cleavage and deprotection.
All of the core peptides were cleaved from the resin with HF, purified by 
preparative HPLC and characterized by ESI-MS.
6. Alkylation of HIV peptide by cores 1 and 2
To 15 mg of C-terminal Cys HIV peptide was added 50 pi of acetonitrile and 100 
pi of water (peptide not fully soluble). Fresh solutions of cores 1 and 2,
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respectively, were prepared (0.9 mM in 0.1 M sodium phosphate buffer, pH 7.0). 
Then the alkylation was started by adding 1ml of core 1 or 2 to the HIV peptide 
suspension: the peptide dissolved completely. After 40 min, the product was 
purified on semi-preparative RP-HPLC, lyophilized, and characterized.
7. General Procedure of Periodate Oxidation
Cores 2-7 underwent periodate oxidation. In general, 3.75 pmol (based on Ser 
content) of core was dissolved in 23.5 ml imidazole buffer (50 mM, pH 6.95, 
chloride counter ion) and 1.3 ml of methionine (200 mM) was added. Then 625 pi 
of Nal04 (0.2 M in water) was added to start oxidation. The reaction was allowed 
to proceed for 5 min and was then quenched by adding 500 pi of ethylene glycol 
(500 mM in water). The product was purified on preparative HPLC and 
characterized by mass spectrometry.
8. Oximation
All of the aldehydes generated from oxidation were reacted with corresponding 
aminooxyacetyl peptides to form an oxime bond (see Figure 1).
On Figure 2, for tetraoxime tree/comb and octaoxime tree/comb/l/ll solutions of 
the aminooxyacetyl peptide (4 mM in NaOAc buffer) and the oxidized core (1 mM 
in NaOAc buffer) were prepared. Oxime formation was initiated by mixing 300 pi 
of core (0.3 pmol core, 2.4 pmol aldehyde groups) with 1.2 ml of peptide (4.8 
pmol) derivative. After 24 h at room temperature, the product was isolated by 
semi-preparative RP-HPLC and characterized by mass spectrometry.
For ‘4+4’ oxime, aminooxyacetyl core 1 (0.2 pmol) with attached HIV-peptide was 
dissolved in 40 pi of acetonitrile and 160 pi of NaOAc buffer (acetic acid 0.57 ml 
in 100 ml of water, sodium acetate 0.82 g dissolved in 100 ml of water, mixed
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part of both until pH 4.0). An equal amount of oxidized core 2 with HIV-peptide 
attached was dissolved in 19 pi acetonitrile and 77 pi of NaOAc buffer. Both 
solutions were mixed, followed by addition of acetic acid to a final concentration 
of 4%. After 24-h reaction at room temperature, the product was purified by semi­
preparative RP-HPLC and characterized by mass spectrometry.
9. Bioassay
4 BALB/c mice were immunized in each case with 50 pg of multimer peptides 
above emulsified in Complete Freund’s Adjuvant (CFA). Animals were boosted 3 
-  4 times at average 3 weeks intervals (days as indicated in Tables) with 25 pg of 
the same peptides emulsified with Incomplete Freund’s Adjuvant (IFA). Blood 
was collected 1 week after each boost for antibody titer determination, and the 
antibody titers reported here were the mean value of results from 4 antisera 
determined by ELISA assay.
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Results and Discussion
A convenient approach to the synthesis of peptide multimers involves oxime 
chemistry. Oxime formation requires an aminoxyacetyl group and a ketone or an 
aldehyde. The latter is easily generated from N-terminal or side chain-linked Ser, 
Thr, or carbohydrates [15-17], and can then react with the aminooxyacetyl- 
containing species. Oxime chemistry was thus introduced in the study to assist 
design and synthesis of multimeric immunogens. Pre-purified polypeptides 
possessing, say, an aminooxyacetyl group are condensed with a core molecule 
that carries multiple copies of, say, an aldehyde group, although of course the 
polarity may be inverted: aldehyde peptides condensed with an aminooxyacetyl 
core [16].
1. Synthesis of aminooxyacetyl-containing peptides
The aminooxyacetyl (NH2OCH2CO- or AOA-) peptides we used in this study are 
synthetic antigenic peptides, either from envelope glycoprotein gp120 of HIV-1 or 
from Influenza hemagglutinin protein. The AOA group exists in commercial 
aminooxyacetic acid that was protected with Boc group then reacted with 
dicyclohexycarbodiimide (DCC) and N-hydroxysuccinimide to form Boc-AOA- 
OSu, which is a convenient acylation reagent.
2. Generation of carbonyl groups (oxidation)
Oxidation by periodate of 1,2-aminoalcohol (Ser, Thr), or of the 1,2-diols of 
carbohydrate groups of glycoproteins is the most convenient method by which a 
carbonyl group can be introduced into an unprotected peptide or protein [18]. 
Such an oxidation rapidly (< 5 min) generates at pH 7.0 an aldehyde, which can 
then react with a 1,2-aminothiol to form a thiazolidine [18] or aminooxyacetyl 
group to form an oxime [16]. Methionine was used for protection against
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sulphoxide formation. After oxidation of N-terminal Ser, product was isolated by 
HPLC. For example, the peak arrowed in Figure 4 was identified by retention 
time and mass spectrum as the aldehyde of core-3.
3. Multimeric constructions employing HIV1-derived peptides as 
building blocks
Oxime bond formation involves the specific reaction between an aminooxy group 
and a carbonyl group (aldehyde or ketone) and expulsion of a water molecule. In 
water, the oximation is very slow at neutral pH but proceeds close to completion 
at acidic pH over a period of hours [14]. Several oxime constructs that possess 
multiple copies of a single oligopeptide were designed and conjugated in this 
way. Using oxime chemistry, or a combination of oxime and thioether chemistry, 
it was possible to assemble multimeric constructs that possessed four or eight 
copies of the HIV1-derived peptide described by Kelker et al [7]. Because the 
peptide subunit was purified and characterized prior to assembly, it was possible 
to characterize products by mass spectrometry. The structures of the multimeric 
constructs are shown in Figure 2.
The first construct (tetraoxime tree, Figure 2) was built on a radial polylysine core 
containing a Ser residue at the tip of each of 4 branches. These Ser residues 
were periodate-oxidized and then reacted with HIV1 -derived peptide in aminooxy 
form to yield a tetramerized product (tetraoxime). HPLC and ESI-MS analysis 
revealed the desired product (Figure 5): Mr found 12059, Mr theoretical 12059. It 
was stable at acidic and neutral pH over 24 h.
Octaxime tree (see Figure 2) was formed in a similar way to the tetraoxime tree, 
but possessed 8 copies of HIV1-derived peptide connected to the lysine core 
through their C-termini. Thus Octaxime tree is comparable in structure with the 
MAP described by Kelker, but, in contrast with the MAP, Octaxime tree can be 
characterized by mass spectrometry (Figure 7). Relative molecular mass found
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24156, theoretical 24157. Some evidence was found of components with higher 
masses [+73, +156, +(156+73)]. These components, which coeluted on HPLC 
with the desired product, were probably due to acylation of the Boc-NHOCH2CO- 
nitrogen with a second Boc-NHOCH2CO- group during synthesis of the HIV1 
peptide (calculation, +73 for NH2OCH2CO replacing H) and of incomplete 
removal of the tosyl group (calculation, +154). We now use less strong acylation 
conditions (1 equivalent instead of five) and thereby avoid the +73 component.
Tetraoxime comb (see Figure 2) was assembled on a linear polylysine core by 
conjugating HIV1-derived peptides at the tip of each of 3 side chains and the N- 
terminus using periodate-oxidation and oximation in a similar manner to the 
tetraoxime tree (characterization, see Figure 6). Evidence of components 
possessing extra -NHOCH2CO- groups (+ 73 amu) was obtained.
Octaxime comb (see Figure 2) was formed in a similar way to the tetraoxime 
comb, but possessed 8 copies of HIV1-derived peptide connected to the lysine 
core through their C-termini (characterization, see Figure 8). Evidence of 
components possessing extra -NHOCH2CO- groups (+ 73 amu) was obtained.
Octaoxime I and Octaoxime II (see Figure 2) were formed in a similar way to the 
octaoxime tree with some differences. In octaoxime II, the oxime bonds were in 
between a three-Glycine spacer and the N-terminal residue, Arginine, of the 
HIV1-derived peptide, in contrast with octaoxime tree in which oxime bonds were 
in between polylysine residues and a three-Glycine spacer. In octaoxime I, the 
oxime bonds were in the same position as octaoxime tree, but the HIV1-derived 
peptide was conjugated in a reverse way to the both alpha and epsilon position 
of Lys residues of the core in comparison with octaoxime tree. HPLC and MALDI 
analysis revealed the desired product (Figure 9, 10). Relative molecular mass of 
octaoxime I: found 23174, theoretical 23138. The found mass was +36 higher in 
this product than that expected. Besides main products, some minor signals were 
present in the MALDI mass spectrum which may be due to loss of 1 or more
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conjugated peptides: it is known that oxime bonds are susceptible to cleavage 
during MALDI analysis [19]. Relative molecular mass of octaoxime II: found, 
24600, theoretical 24543. The mass of found compound was +57 higher than the 
desired. Signals corresponding to loss of 1 or more conjugated peptides were 
also present.
Preliminary biological results (immunogenicity assays performed in mice at New 
York University by Kelker) showed that the tetraoxime, unlike the tetraMAP of the 
previous study, was capable of inducing the desired antibody response: 
antiserum recognized native gp-120 but not denatured gp-120, and neutralized 
viral infectivity. However, the titres were lower than those obtained in the 
previous study (data not shown) with the uncharacterizable octaMAP. This led us 
to attempt to connect two copies of a tetramer through a short linker, our ‘4+4’ 
construct (see Figure 2), while awaiting bioassay of the tetraoxime comb, 
octaoximes tree and comb, etc.
The two tetramers of the ‘4 + 4’ construction were linked by an oxime bond. Each 
tetramer was a radial polylysine core possessing a copy of HIV1-derived peptide 
at the tip of each of 4 branches, which was conjugated through a thioether bond 
arising from a specific reaction between bromoacetyl and thiol groups. One of the 
tetramers had a Ser residue on the core and this was oxidized by periodate to 
generate an aldehyde, which was then reacted with an aminooxy group on the 
core of the other tetramer to form the oxime-linked ‘4 + 4’ construct. The 
oximation in this case proceeded essentially to completion and the product was 
characterized by HPLC and ESI-MS (Figure 11). The relative molecular mass 
found was 23871, close to the calculated mass 23876. No evidence of an extra 
NHOCH2CO group (+73 amu) was found, which is not surprising since the 8 
copies of HIV-1 peptide employed had not undergone acylation with Boc-AOA- 
OSu.
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A control oxime was also constructed which consisted of a linear polylysine core 
but only a HIV-derived peptide conjugated. The relative molecular mass found 
was 4334, similar to the calculated mass 4334. Evidence of components 
possessing extra -NHOCH2CO- groups (+ 73 amu) was obtained
3. Bioassay
In our previous study, an octamer MAP (also refered as to MCP), when injected 
into mice, was able to induce high titers of antibodies against native gp120 of HIV 
type 1 (Table 3). This MCP, however, cannot be purified and characterized 
precisely due to unavoidable synthesis failure, and thus cannot be envisaged for 
clinical use. In this study, we adopted site-specific conjugation using oxime 
chemistry to synthesize a series of tetramers or octamers that were comparable 
to MCP in structures. Analyses of these octamers showed they were purifiable 
and characterizable. And they were then injected into mice for the assessment of 
immunogenicity.
ELISA assays (Table 4) revealed that 2 of these multimers: octaoxime comb and 
tetraoxime comb, can induce high titers of antibodies recognizing native gp120 
although the titers were 2 fold less than that from MCP at 107 days after 
injection. Another multimer, tetraoxime tree design can also elicit antibodies 
against native gp120 but the titers were lower, 12 fold less than that from MCP 
and 6 fold less than that from octaoxime comb and tetraoxime designs, the latter 
is, however, different in another experiment (Table 6). This may be due to 
different types of gp120 protein (type LAV and MN) used in the two different 
experiments. The other multimer designs: ‘4+4’ oxime, octaoxime I and II, 
octaoxime tree design, were all demonstrated not capable of inducing correct 
antibodies against native gp120 (Table 5 and 6). It is not clear why the different 
copies of multimers and different designs elicit different antibodies against native 
gp120, which might be due to the conformations of these multimers. Octaoxime 
comb, tetraoxime comb and tetraoxime tree designs may possess a
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conformation similar to the selected epitope of native gp120 and thus induce 
antibodies to recognize the protein. Antibodies elicited from octaoxime comb, 
tetraoxime tree and MCP can only recognize native gp120 and not the denatured 
protein whereas antibodies raised against monomer peptide mainly recognize 
denatured gp120 (Table 7), which further confirmed these multimers may display 
a similar conformation to the epitope of native gp120. Since these multimers are 
comparable in covalent structures and immunological properties to the MCP but 
in contrast are purifiable and characterizable, they are promising candidates for 
AIDS vaccine development.
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Conclusion
Model octameric constructions employing HIV1-derived peptides as building 
blocks can be made in pure form in good yield using oxime chemistry but not by 
direct synthesis (MAP) nor by thioalkylation. Antibodies elicited by three 
polyoximes of the 419-439 sequence: tetraoxime tree- and comb-design, and 
octaoxime comb-design, are capable of neutralising the virus in high titres in 
mice. These polyoximes are comparable to previous octamer MAP (or MCP) in 
covalent structures as well as in immunogenicity.
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Tables and Figures
Table 1: Synthetic peptide sequences from residues 419-439 of gp120.
Table 2: Core structures used in the study.
Table 3. MCP with eight peptide chains elicits antibodies recognizing envelope 
glycoprotein.
Table 4. Tetraoxime tree and comb design or octaoxime comb design elicit 
antibodies recognizing gp120.
Table 5. MCP but not ”4+4” oxime nor octaoxime I nor octaoxime II elicit 
antibodies recognizing gp120.
C57BI/10 mice were immunized with 25 pg of peptide constructs listed in Table, 
emusified in CFA. Mice were boosted 3 times (at 3 week intervals) with peptide 
emulsified in I FA. Mice were bled at ~2 weeks after the boosts and the antibody 
titers were determined by ELISA with antigens listed in Table.
Table 6. Tetraoxime tree and octaoxime comb elicit high titers of antibodies 
recognizing gp120
Table 7. Polyoxime constructs elicit antibodies that recognize conformational 
determinant(s) in gp120.
Antisera to the antigens listed were raised in BALB/c mice and their recognition 
of the "native” or denatured gp120 was determined by ELISA. ELISA wells were 
coated with rGp120 MN at 1 pg/ml in PBS either: maintained at 4°C ("native” 
control), or denatured by heating at 95°C for 5 minutes with 1 mM DTT, 0.01%  
SDS.
Figure 1. A general scheme for site-specific modification of peptides and 
proteins through orthogonal coupling of an aminooxyacetyl group and an 
aldehyde to form an oxime. (a) oxidation of N-terminal Ser (R=H) or Thr (FUCH3) 
with periodate, (b) reaction of an aminooxy compound with an aldehyde to form 
an oxime.
Figure 2. Structure schemes representing polyoxime (radial- or comb-branched) 
using a model of peptide, RIKQIINMWQEVGKAMYAPPI, from HIV-1 gp120. 
They are modified as seen in Table 1 * ^ *  is peptide 1; v /S A  is peptide 2; 
Mnmi is peptide is peptide 4. The branching Lys residues of the cores
are acylated on both alpha and epsilon amino groups with corresponding 
peptides and are shown unconventionally with their carboxyl groups to the left for 
Tetraoxime tree and Octaoxime tree / I /  II, and also for ‘4+4’ oxime. The
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structure of the C-terminal Cys peptide in ‘4+4’ oxime has been simplified after 
alkylation. Figure 2A shows a control-oxime for polyoxime.
Figure 3. Structure of the control-oxime (comb-branched) using peptide 
RIKQIINMWQEVGKAMYAPPI from HIV-1 gp120. The peptide is modified as 
seen in Figure 2. Only the side chain of Lysine in the middle site has the peptide 
attached. The N-terminal of Glycine and the side chain of 6 other Lysine residues 
are blocked with -CO CH3.
Figure 4. (A) RP-HPLC analysis of periodate oxidation of core-3 to yield a radial- 
branched octa-aldehyde; (B) ESI Mass spectrum of the octaaldehyde (calculated 
1434.5, found: 1434.1, 1452.1 and 1470.3. The masses 1452.1 and 1470.3 are 
the octaaldehyde plus 1 and 2 water molecules, respectively).
Figure 5. (A) RP-HPLC analysis of the Tetraoxime tree (see Figure 2 for 
structure); (B) ESI mass spectrum of the Tetraoxime tree (calculated Mr, 12059, 
found, 12059).
Figure 6. (A) RP-HPLC analysis of the Tetraoxime comb (see Figure 2 for 
structure); (B) ESI mass spectrum of the Tetraoxime comb (calculated Mr, 
12216, found, 12218).
Figure 7. (A) RP-HPLC analysis of the Octaoxime tree (constructed on radial 
core), see Figure 2 for structure; (B) ESI mass spectrum of the Octaoxime tree 
(calculated Mr, 24157, found, 24156).
Figure 8. (A) RP-HPLC analysis of the Octaoxime comb (constructed on linear 
core), see Figure 2 for structure; (B) ESI mass spectrum of the Octaoxime comb 
(calculated Mr, 24314, found, 24313).
Figure 9. (A) RP-HPLC analysis of the Octaoxime I (constructed on radial core), 
see Figure 2 for structure; (B) MALDI mass spectrum of the Octaoxime I 
(calculated Mr, 23138, found, 23174).
Figure 10. (A) RP-HPLC analysis of the Octaoxime II (constructed on radial 
core), see Figure 2 for structure; (B) MALDI mass spectrum of the Octaoxime II 
(calculated Mr, 24543, found, 24600).
Figure 11. (A) RP-HPLC analysis of the ‘4 + 4’ octaoxime (see Figure 2 for 
structure); (B) ESI mass spectrum of the ‘4+4’ oxime (calculated Mr, 23876, 
found, 23871).
Figure 12. (A) RP-HPLC analysis of the control oxime (see Figure 3 for 
structure); (B) ESI mass spectrum of the control oxime (calculated Mr, 4334, 
found, 4334).
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* Control MCP, with a single peptide chain on a polylysine core.
Table 4. Tetraoxime tree and comb design or octaoxime comb design elicit antibodies recognizing gp120
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Table 5: MCP but not ‘’4+4” oxime nor octaoxime I nor octaoxime II elicit antibodies recognizing gp120
Immunogen
Antigen
MCP Monomer Gp120 ”4+4” oxime Octaoxime I Octaoxime II
Titers
MCP 125,000 4,300 2,600 ND ND ND
”4+4” oxime ND <20 <20 150 ND ND
Octaoxime I ND 800 20 ND 20 ND
Octaoxime II ND 20 33 ND ND 40
Table 6. Tetraoxime tree and octaoxime comb elicit high titers of antibodies recognizing gp120
Antigen






Octaoxime I . 31 180 55
59 8,500 58
116 4,000 33
Octaoxime tree 31 2,100 25
59 220,000 60
116 328,000 125
Octaoxime 31 42,000 1,400
comb 59 220,000 2,500
116 328,000 1,750
Tetraoxime 31 250,000 125
tree 59 250,000 2,560
116 370,000 21,000
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Table 7. Polyoximes constructs elicit antibodies that recognize conformational determinant(s) in gp120.
Gp120 MN Gp120 MN denatured % Control remaining after
Antisera to __________________________________________________ denaturation______
______________________________ OP 405 m|u___________________________
Octaoxime comb 1.240 0.010 0.7
Tetraoxime tree 1.770 0.090 5.5
MCP 0.990 0.026 2.6
Monomer 1.510 2.080 137.7
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(a) NH2-CH-CO- 
HO-CHR
(b) R’-ONH2 + 0=CH-C0
Figure 1
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Mild oxidation with periodate of the l-amino-2-ol moiety of N-terminal seryl or threonyl peptides and 
proteins leads to a terminal aldehyde function 0 = C H - C 0 -  which usually may be exploited for 
bioconjugate formation (e.g., via oximation with an O-alkyl hydroxylamine). We report that, when 
followed by a prolyl residue, the 0 = C H —CO— group can undergo a rapid cyclization and dehydration 
reaction through nucleophilic attack by the amide nitrogen of the third amino acid residue of the 
chain. We have characterized the resulting heterocycle, which is stable in aqueous acid, by mass 
spectrometry and NMR. Quantitative oximation can nevertheless be achieved in such cases by 
performing a one-pot oxidation-oximation without isolation of the intermediate aldehyde, as is 
demonstrated with cholera toxin B subunit.
INTRODUCTION
The oxidation by periodate of N-terminal 1,2-amino 
alcohols Ser (R =  CH2OH) or Thr [R =  CH(OH)CH3l 
residues N H 2-C H R -C O -  of a polypeptide to an alde­
hyde function 0 = C H - C 0 -  has been known for many 
years ( I) . More recently, this mild oxidation reaction has 
been exploited for the synthesis of bioconjugates through 
formation of hydrazone, thiazolidine, or oxime ( -O N =  
C H -C O -) bonds (e.g., refs 2-8 ). Usually, the polypeptide 
aldehyde is stable in aqueous solution at pH values 
between 2 and 5 and may be lyophilized and stored as a 
powder at —20 °C (4). In  some cases, however, the 
aldehyde can undergo side reactions. For example, for­
mation of a 1,3,4-oxadiazolino peptide containing two 
peptide aldehyde units has been observed during at­
tempted hydrazone formation (9).
We have observed that some polypeptides and proteins, 
including Cholera toxin B subunit (CTB), undergo rapid 
and quantitative oxidation to yield a compound which 
may be isolated and has the mass calculated for the 
expected 0=CH-CO-polypeptide species, but oximation 
occurs very slowly indeed (half time estimated in weeks 
under conditions where normally the half time is of the 
order of very few minutes). The first protein which gave 
such difficulties was a /Mactamase (5), and in that case, 
the problem was solved by careful optimization of the 
conditions of oxidation of the N-terminus and storage of 
the aldehyde, but such an approach was not successful 
with CTB. We were able to reproduce the phenomenon 
of oxidation followed by very slow oximation using a small 
synthetic peptide consisting of the first six residues of 
the /Mactamase, Thr-Pro-Val-Ser-Glu-Lys-amide. In  this 
article, we show that, when followed by a prolyl residue, 
the 0 = C H —C O - group formed by oxidation of N-term i­
nal Ser or Thr can undergo a rapid cyclization and
* To whom correspondence should be addressed. Phone: +41 
22 702 5523. Fax: +4122 346 8758. E-mail: rose@cmu.unige.ch.
1 Department of Medical Biochemistry.
* Department of Organic Chemistry.
dehydration reaction through nucleophilic attack by the 
amide nitrogen of the third amino acid residue of the 
chain. The resulting heterocycle, which is stable in 
aqueous acid, was characterized by mass spectrometry 
and NMR. To achieve quantitative oximation in such 
cases, we developed a one-pot oxidation-oximation with­
out isolation of the intermediate aldehyde and demon­
strate here with CTB that it is possible to prepare in good 
yield a hybrid construct of which 60% of the mass is the 
B subunit and 40% is totally synthetic. CTB conjugates 
are potentially useful as vaccines: CTB can supply T  
helper epitopes and, if  the construct assembles as its 
noncovalent pentamer, such constructs would be expected 
to elicit a mucosal immune response (e.g., refs 10 and 
11).
EXPERIMENTAL PROCEDURES
M ateria ls . Synthetic peptides were prepared using 
Boc chemistry on a model 430A synthesizer (Applied 
Biosystems Inc.) modified according to Kent (12). 15N (99 
atom %) A^-Boc-L-valine was purchased from Isotec. 
Methylbenzhydrylamin e resin (NovaBiochem, Switzer­
land) was used to obtain peptide amides directly upon 
cleavage with HF. Synthetic peptides were purified by 
high-pressure liquid chromatography (HPLC), aceto- 
nitrile was removed by rotary evaporation at room tem­
perature, and product was recovered by lyophilization. 
Purified peptides gave a single peak on analytical HPLC  
and the expected mass spectrum. The aminooxyacetyl 
peptide N H 2OCH2CO-Gly3 fLys(Ser)l5Gly-OH was pre­
pared as previously described (13). Cholera toxin B sub­
unit (CTB, Inaba strain) was obtained from the Swiss 
Serum and Vaccine Institute, Berne, Switzerland. So­
dium metaperiodate and guanidine hydrochloride 
(MicroSelect grade) were purchased from Fluka, Buchs, 
Switzerland. Boc-aminooxyacetic acid was from Calbio- 
chem-NovaBiochem, Laufelfingen, Switzerland.
C hrom atography. High-pressure liquid chromatog­
raphy was performed using a column of Nucleosil 300A 
5 jim Cg (Macherey Nagel, Oensingen, Switzerland), 250
10.1021 /bc9900587 CCC: $18.00 © 1999 American Chemical Society
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x 4 mm id for analytical work (0.6 mL/min, 2 mL loop) 
and a radial compression system (210 x 25 mm id, Nova- 
Pak H R  60A 6 fxm Cis, 20 mL/min, 50 mL loop) for 
preparative work, monitoring at 214 or 229 nm for 
analytical or preparative work, respectively. Linear 
gradients were established between solvent A [1 g of 
trifluoroacetic acid (TFA) added to 1 L of HPLC grade 
water and then vacuum filtered and degassed] and 
solvent B (1 g of TFA  added to 100 mL of water, brought 
to 1 L w ith gradient grade acetonitrile then vacuum 
filtered and degassed). Gel filtration was performed on 
a Superdex 75 H R  10/30 column (Pharmacia, Uppsala, 
Sweden) a t a flow rate of 0.4 mL/min using 0.25 M  
phosphate buffer, pH 7.0 (counterion sodium), which was
1 mM in EDTA, monitoring at 280 nm.
M ass S pectrom etry . Spectra were obtained using 
electrospray ionization on either a Trio 2000 (infused at
2 /^L/min) or Platform I I  instrument (infused at 7 fiL/  
min); both machines were from Micromass, Altrincham, 
U.K. Samples of synthetic peptides were dissolved in 
water/acetonitrile 1:1 by volume, whereas protein samples 
were dissolved in water/acetonitrile/acetic acid (49.5: 
49.5:1 by volume).
N M R  spectroscopy (14) was performed on a Bruker 
AM X-2—600 spectrometer operating at 14.1 T. Peptide 
samples were dissolved in D20  at pD 4.7 (DC1). After 
acquisition of all data, samples were reanalyzed by HPLC  
to check for possible decomposition. Two-dimensional 
experiments were performed at 298 K. 1H /1H-DQ F— 
COSY spectra were acquired using 512 x 16K data points 
and a spectral width of 12 ppm in both dimensions. A  
shifted sine bell function was applied to the indirectly 
detected dimension during data processing. The hetero- 
tiuclear HSQC (15—17) and HMBC experiments (18—19) 
were performed with 128 x 4K data points and spectral 
widths of 90 x 10.69 ppm in the carbon and proton 
jlimension, respectively. Folded signals could easily be 
dentified as such. For the processing, sine bells were 
ipplied in both dimensions.
O x id a tio n  o f TPVSEK-am ide. To a solution of puri- 
ied hexapeptide amide (17.6 mg, 26.8 /<mol of peptide, 
!8 mL of water, 2.8 mL of 10% ammonium bicarbonate 
iolution) was added 5.6 mL of sodium metaperiodate 
iolution (0.184 g/L in water, 4.8 //mol) with vortex mixing, 
s^ soon as possible, the reaction was quenched by mixing 
n 5.6 m L of ethyleneglycol (10 M  in water) and injecting 
he reaction mixture onto preparative HPLC. After a 5 
pin isocratic period, a linear gradient of 1% B/min was 
established. Once the three components had eluted 
within 30 min), the column was washed briefly at 50% 
J then reequilibrated at 100% A. Organic solvent was 
emoved by rotary evaporation at room temperature and 
iroduct recovered by lyophilization. From 85 mg of 
>eptide, we isolated 39 mg of peak 1, 4.6 mg of peak 2 
nd 4.6 mg of peak 3.
O x im a tio n  o f O xidized TP V S E K -am ide. For the 
tudy at pH 4.6, the buffer was 0.1 M acetate, counterion 
odium. In  separate experiments, both forms of the 
xidized hexapeptide amide (peaks 2 and 3, 0.3 mg in 60 
L buffer) were treated with aminooxyacetic acid (60 fiL, 
m M  in buffer). For the study at pH 7.0, a phosphate 
uffer was used (0.1 M, counterion sodium) in place of 
cetate. The oximation reactions were monitored by 
|PLC, injecting 10 juL volumes with a gradient from 0 
i 35% B over 30 min.
O x id a tio n  a n d  O xim ation o f CTB. CTB was sup- 
ied as a lyophilized powder in the presence of buffer 
tits, including Tris which might be expected to react 
ath periodate. Vial contents (1 mg of protein) were
1
0 10 20 min
Figure 1. Preparative HPLC chromatogram of the oxidation 
of TPVSEK-amide with a limited quantity of periodate. After a 
5 min isocratic period at 100% A, a gradient of 1%/min solvent 
B was applied, monitoring at 229 nm. Mass spectrometry and 
NMR identified components as peak 1, unmodified peptide; peak
2, hydrated glyoxylyl peptide (HOhCHCO-FVSEK-amide; peak
3, cyclic isomer of the expected 0=CHCO-PVSEK-amide.
therefore dissolved in 1 m L of water, and the protein was 
isolated by gel filtration as the noncovalent pentamer. 
The protein was concentrated by ultrafiltration (Centri- 
con, Amicon, Beverly, MA, 10000 molecular weight cutoff, 
precentrifuged twice with 1 mL of phosphate chroma­
tography buffer to remove glycerol which interferes with  
the oxidation step) to 400 fiL. Methionine (50 fiL , 0.2 M  
in the phosphate buffer) was added to protect against 
thioether oxidation, then oxidation of the N-terminal Thr 
residue was initiated by addition of sodium periodate (25 
fiL, 40 mM in the phosphate buffer). After 5 min in the 
dark, excess periodate was quenched with ethyleneglycol 
(60 fiL, 0.5 M  in water), then 4 min later, 27.8 mg of 
aminooxyacetyl peptide N H 2OCH2CO-Gly3 [Lys(Ser)]5Gly- 
OH was added, followed by 50 fiL of acetic acid. An 
aliquot (15 ^L) was removed for HPLC and mass spec- 
trometric analysis after 30 min, whereupon the sample 
was placed at —20 °C overnight. The next day, 500 mg 
of guanidine hydrochloride was added and the protein 
oxime isolated by gel filtration and ultrafiltration to a 
volume of about 400 fiL. Oxidation of the Ser residues 
on the Lys side chains of the peptide attached to CTB 
was achieved by adding methionine (150 fiL, 0.2 M  in  
phosphate buffer) followed by periodate (62.5 uL, 80 mM  
in phosphate buffer). After 5 min in the dark, the reaction 
was quenched with l,3-diamino-2-propanol (Fluka, 300 
fiL, 0.5 M  in water adjusted to pH 7.8 with acetic acid). 
Four minutes later, 500 mg of guanidine hydrochloride 
was added, and the oxidized protein isolated again by 
gel filtration and concentrated by ultrafiltration to about 
400 fiL. A second 400 fiL sample (from a separate 
experiment) was pooled at this stage. To the pool (800 
fiL), aminooxyacetyl peptide CH3CO-DC(CH2CONH2)- 
TLIDALLG DPHK(CO CH2O NH2)-NH2 was added (5.7 
mg), and the solution made 4% in acetic acid. For every 
microliter of this solution, 1 mg of guanidine hydrochlo­
ride was added and the oximation left overnight. Final 
product was isolated by semipreparative HPLC (1 mg 
after lyophilization) and characterized by mass spectrom­
etry.
RESULTS AND DISCUSSION
O x id a tio n  o f TPV S E K -am ide. To study the rapid 
oxidation of the terminal l-amino-2-ol moiety of 1, 
oxidation with periodate was performed with lim iting  
amounts of periodate and a reaction time of a few seconds 
(to allow mixing). This allowed isolation of three compo­
nents by HPLC (Figure 1). Peak 1 was identified by 
retention time and mass spectrum as unreacted starting
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peptide (abundant signal at mlz 660.0 corresponding to 
the protonated molecular ion, most intense peak at mlz 
330.9, the doubly protonated molecule, data not shown). 
Peak 2 gave a mass spectrum with signals at mlz 614.5, 
632.5, and 654.4. The most intense peak mJz 632.5 
corresponds to the hydrated form of the aldehyde, 
(HO ^C HC O —PVSEK-amide (2) with one proton, and mlz 
654.4 corresponds to sodium cationization of the same 
species. The small signal at mlz 614.5 in the spectrum of 
peak 2 became the most intense peak in the spectrum 
of peak 3, where it was accompanied by mlz 636.6. These 
two signals correspond to 0=C H C 0-P VSE K -am ide (i.e., 
the aldehyde) with one proton and with one sodium ion, 
respectively, although we show below that peak 3 is 
actually a cyclic isomer (3) of the aldehyde. Peak 2 
m aterial, upon storage in aqueous solution at pH 4.6 
(sodium acetate buffer), was found by HPLC and mass 
spectrometry to transform to peak 3 material over a 
number of days, but was more stable in 0.1% TFA at pH  
2 (not shown). Thus, the signal at mlz 614.5 in the 
spectrum of Peak 2 material could be due to dehydration 
of the hydrate within the mass spectrometer to give 
either the aldehyde itself or its isomer (3). Peaks 1, 2, 
and 3 were found to be stable for days in aqueous solution 
at pH 2 at room temperature, and for months as lyo- 
philized powders at —20 °C (not shown).
O x im a tio n  of oxidized TP V SEK -am ide (peaks 2 
and 3) was studied at pH 4.6 and pH 7.0. It  has 
previously been shown that oximation proceeds faster at 
lower pH, and very slowly indeed at neutral pH (7). 
Oximation of peak 2 (the hydrated aldehyde) with amino- 
oxyacetic acid at pH 4.6 was found to proceed extremely 
rapidly. Figure 2a shows almost quantitative reaction 
after 130 min: reaction halftime was approximately 10 
min judging by earlier time points (not shown). The 
expected oxime product was identified by mass spectrom­
etry through its protonated molecular ion at mJz 687.7. 
A trace of peak 3 material is also formed, which elutes 2 
min after the oxime (ox). Oximation of peak 3 (which has 
the mass of the aldehyde) proceeded extremely slowly at 
pH 4.6, w ith very little product formed after 130 min 
(Figure 2b). The oxime was nevertheless being formed 
(it elutes 2 min earlier than peak 3 and is just visible in  
Figure 2b), and it represented about 12% after 35 h 
(product confirmed by mass spectrometry, not shown).
A t pH 7.0, almost exactly the same chromatograms 
were obtained during oximation of peak 2 (Figure 2c) and 
peak 3 (Figure 2d). After 10 min, both showed presence 
of peak 2 and peak 3, with virtually no oxime product. 
At this pH, peaks 2 and 3 clearly interconvert rapidly: 
equilibrium is almost attained after 10 min, but not quite 
since we notice that Figure 2c is slightly richer in the 
starting peak 2 whereas Figure 2d is still slightly richer 
in the starting peak 3. In  both cases, oxime formation 
proceeded very slowly, reaching about 30% after 10 h (not 
shown). Thus, although oximation proceeded very slowly 
at pH 7.0 for both peaks 2 and 3, it nonetheless proceeded 
more rapidly than for peak 3 at pH 4.6 (but much less 
rapidly than for peak 2 at pH 4.6).
These results were difficult to understand. For years 
it has been known that small aliphatic aldehydes (such 
as heptanal), many peptides and proteins carrying a 0 =  
C H —CO—N H —CHR—CO— group (where R is the side 
chain of a genetically coded amino acid), many polypep­
tides carrying a —N H C H 2CH = 0  group, and many pep­
tides carrying a 0 = C H —CO— group attached to the side 
chain of Lys undergo rapid and almost quantitative 
oximation at mildly acid pH. In the case of the oxidized 
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F igu re 2. Analytical HPLC chromatograms of oximation 
reactions of peaks 2 and 3 of Figure 1. Remaining material is 
labeled 2 or 3, accordingly. Oxime product (ox) was identified 
by mass spectrometry. After a 5 min isocratic period at 100% 
A, a gradient of 1.17%/min solvent B was applied, monitoring 
at 214 nm. (a) Peak 2, pH 4.6,130 min. (b) Peak 3, pH 4.6,130  
min. (c) Peak 2, pH 7; 10 min. (d) Peak 3, pH 7, 10 min.
aldehyde (peak 2) was able to undergo rapid oximation 
at pH 4.6, but the apparent aldehyde (peak 3) was not. 
This led us to investigate by NMR spectroscopy the 
structure of peaks 1, 2, and 3.
N M R  Analysis. The 1H /1H -D Q F-C O SY spectra of 
compounds 1, 2, and 3 allowed assignment of all reso­
nances of hydrogen atoms bound to carbon (14). Since 
the amino acid residues differ all in their spin systems, 
the assignment was straightforward and unambiguous. 
Data for XH  chemical shifts are compiled in Table 1.
Comparison of the 1H-spectra of 1 and 2 immediately 
confirmed the Thr residue as the site of oxidative 
cleavage. The three signals of Thr of 1 are missing in 
compound 2 and are replaced by a singlet at <5 (ppm) 5.58. 
This is the resonance of the H —C(2) proton of the newly 
formed dihydroxyacetyl residue [the former H —C(a) of 
Thr]. That we were dealing with a hydrated aldehyde was 
corroborated by an HSQC-experiment (15—17) which 
correlates this proton to a 13C signal at <5 (ppm) 86.0 via
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3.5 2.5 2 1.55 4.5 4 36 5.5 1 ppm
F ig u re  3. :H NMR spectra recorded at 600 MHz in D2 O of (a) compound 2 and (b) compound 3, with assignment of those resonances 
which change significantly upon cyclization.
Table 1. lH Chemical Shifts for the Amino Acid Residues 
of Com pounds 1, 2, and 3 at 600 MHz in D2 O (pD 4.7)
residue position 1 2 3






Pro (P) H-C(a) 4.58 4.52 4.58
HzQifi) 1.93/2.36 1.97/2.34 2.03/2.47
H2C (y) —2.10 -2.03 2.04/2.13
H2C(<3) 3.72/3.83 3.75/3.77 3.57/3.61
Val (V) H-C(a) 4.12 4.17 4.63
H—C(£) 2.10 2.14 2.25
H3C(y) 0.97/1.00 0.99/1.01 0.81/1.01
Ser (S) H-C(a) 4.46 4.47 4.49
H2C(/3) 3.86/3.88 3.86/3.88 3.89
Glu (E) H-C(a) 4.45 4.44 4.45
H2CQ?) 2.00/2.19 1.96/2.18 2.04/2.18
H2C(y) 2.50 2.51 2.55
Lys (K)—(amide) H-C(a) 4.30 4.30 4.31
H2CQS) 1.78/1.86 1.79/1.88 1.80/1.89
H2C(y) 1.42/1.46 1.45/1.49 1.47/1.50
H2C(<5) 1.70 1.70 1.72
H2C(e) 3.03 3.01 3.04
0 Dihydroxyacetate for 2, and H—C(2) of the new six-membered 
heterocycle for 3.
1J  scalar coupling. The chemical shifts of the remain­
ing five residues (Pro, Val, Ser, Glu, and Lys-amide) show 
a remarkable similarity between compounds 1 and 2. 
Clearly, these amino acid residues were not altered.
However, when comparing compounds 2 and 3 (Table 
1 and Figure 3), it  was evident that the dehydration 
reaction resulted in significant changes of the Pro and 
Val resonances. One of the methyl groups of Val had 
undergone an upfield shift of 0.2 ppm, whereas H —C(a) 
of Val changed from 4.17 to 4.63. A significant change 
(5.58 — 5.46) was observed also for the H —C(2) resonance 
of the oxidized residue. The signals of the three remain­
ing amino acid residues Ser, Glu, and Lys-amide are 
almost identical for 2 and 3. These findings clearly show 
that only Val and Pro sense the new molecular environ­
ment in 3. Bond formation between the nitrogen atom of 
Val and C(2) of the oxidized residue, i.e. the disguised 
aldehyde, best accounts for our observations (Scheme 1).
The conclusions found strong support by a HMBC  
experiment {18, 19), which unveiled scalar 1H /13C cou­
pling between H —C(a) of Val and C(2) of the oxidized 
residue. The absolute value of this 3 Jem coupling is 4.6 
Hz. The existence of the crucial C(2)—N(Vai> bond was
Schem e 1. S tru ctu res o f U noxid ized  P ep tid e  (1), 
H ydrated G lyoxylyl P ep tid e (2), and C yclic Isom er o f  
G lyoxylyl P ep tid e (3)
eventually ascertained by specific 15N-labeling of com­
pound 3 in the N (vai) position. The 13C NMR spectrum of 
this labeled material [15N(vai)-3] shows Vc/n coupling for 
three carbon atoms, which are C(2) [at 6 =  79.9, lJcm =  
7.6 Hz], C(a)rvaJ) fat 6 =  64.4, lJers =  8.4 Hz], and CO(Pro) 
[at 6 =  175.9, lJcm =  12.8 Hz]. In  addition, 15N(Va» couples
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Table 2. Ease of Oximation of Various Oxidized 
P olyp ep tid es
N-terminal oximation after isolation
sequence source of oxidized polypeptide
SAKELR  IL-8 easy
SLAADT  MIP-la easy
SQLHSG  GCSF fragment easy
TPVSEK  ^-lactamase possible0
TPVSEK-amide synthetic difficult
SPYSSD  Rantes difficult
TPQNIT  Cholera toxin B difficult
subunit
0 After much optimization (5).
over two bonds with CCaXpn,, [at 6 =  61.58, 2Jos =  5.4 
HzJ. These values are close to what is expected for 3 (20), 
and they leave no doubt that N(Vap is bound to three 
carbon atoms. The ring closure creates, with high ste­
reoselectivity, a new center of chirality. We see a single 
epimer of 3. The absolute configuration at H -C (2 ), 
however, is unknown.
The cyclization process 2 —* 3 is entropically favored 
by the rigidity of the proline ring, which keeps the two 
reacting centers in proximity. This propensity to cyclize 
is probably responsible for the difficulty sometimes 
encountered to oximate a polypeptide which, by mass 
spectrometry, has the mass of the aldehyde. A ll of our 
difficult oximations have involved X-Pro sequences, 
where X  is Thr or Ser (Table 2, where only a small 
selection of easily oximated polypeptides is shown).
Studying “glyoxylyl-Pro-He-Val-amide” made by treat­
ment of diisopropylthioacetyl peptide with N-bromo- 
succinimide and isolation under acidic conditions, Qasmi 
et al. (21) found the mass of the aldehyde form (which is 
the same as that of the cyclic form) by isobutane Cl mass 
spectrometry, but found evidence by NM R  (in DMSO) and 
FAB mass spectrometry (thioglycerol matrix) that the 
polypeptide can also exist in hydrated form, as we found 
for our synthetic peptide. By proton NMR, they found 
no aldehydic proton at all for “glyoxylyl-Pro-He-Val- 
amide”, but found a singlet at d(ppm) 9.2—9.3 integrating 
0.5 H  for the aldehyde proton of “glyoxylyl-Phe-Pro-He- 
Val-am ide” and “glyoxylyl-Asn-Phe-Pro-Ile-Val-amide”.
O x id a tio n  o f C TB  and oximation with the carrier 
molecule N H 2OCH 2CO-Gly3[Lys(Ser)]5Gly-OH under the 
“one-pot” conditions described led to quantitative conver­
sion (Figure 4a) to the expected oxime C TB=NO CH 2CO- 
Gly3[Lys(Ser))5Gly-OH: relative molecular mass found 
by electrospray ionization mass spectrometry, 12 938 Da 
(theoretical mass, 12 937 Da). CTB normally exists as a 
noncovalent pentamer, but treatment with acid and 
organic solvents leads to the monomeric form exclusively. 
Oxidation of the side-chain Ser residues of the ligated 
carrier molecule followed by isolation of the oxidized pro­
tein possessing five aldehyde groups and oximation with 
the peptide CH3CO-DC(CH2CONH2)TL ID A L L G D P H - 
K (C O C H 2O N H 2)-N H 2 (NI^OCHpCO-peptide) yielded 1 
mg of product from 2 mg of starting CTB. Characteriza­
tion by mass spectrometry showed this product (relative 
molecular mass, 21 102 Da, theoretical mass, 21 101 Da) 
to be the expected branched hybrid C TB=NO CH 2CO- 
Gly3[Lys(COCH=NOCH2CO-peptide)]5Gly-OH.
A similar product was made earlier (22) using the “one- 
pot” conditions and different form of the peptide, CH3CO- 
;DC(SCH2CH2NHCOCH2ONH2)TLID-ALLGDPH-NH2. At
£hat time, we did not know why it  was necessary to use 
I one-pot” conditions for the first oximation step, while it 
was possible to isolate the oxidized protein prior to the 
second oximation step. By performing the “one-pot”
4
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F igu re 4. Analytical HPLC chromatograms of oximation 
reactions of oxidized CTB with NH2OCH2CO-Gly3[Lys(Ser)]5 - 
Gly-OH. Compounds were identified by mass spectrometry. 
After a 5 min isocratic period at 35% B, a gradient of 0.2%/min 
solvent B was applied, monitoring at 214 nm. (a) “One-pot” 
oxidation-oximation under optimized conditions, showing quan­
titative conversion to the oxime. (b) “One-pot” reaction at 
suboptimal pH and time.
oxidation-oximation at pH 6.5 instead of 7.0, and quench­
ing after 2 min, it was possible to isolate four components 
from the reaction mixture (Figure 4b). Mass spectrometry 
identified peaks 1—4: peak 1 was the expected oxime 
(found, 12 938; calcd, 12 937); peak 2 was unoxidized CTB 
(found, 11 602; calcd, 11 604); peak 3 was hydrated 
glyoxylyl CTB (HO)2C H CO -C TB  (found, 11 580; calcd, 
11 577); and peak 4 had the mass expected for “glyoxylyl- 
CTB” but was most probably the cyclic isomer; found, 
11 558; calcd, 11 559. Incubation of peak 3 material w ith  
N H 2OCH2CO-Gly3[Lys(Ser)]5Gly-OH led to formation of 
peak 1 material (oxime), while oximation of peak 4 
material failed. Use of methanol, which leads to hemi- 
acetal formation, in place of acetonitrile as cosolvent for 
electrospray ionization shifted the mass of peak 3 to, 
found, 11 589 and, calcd, 11591, but did not shift the 
other masses, in particular that of peak 4, providing 
further evidence of lack of a free aldehyde moiety for peak 
4. Taken together with the mass spectrometric and N M R  
results obtained with the model peptide, it  would seem 
that cyclization of glyoxylyl-Pro polypeptides to a cyclic 
isomer which oximate with difficulty may also occur with  
proteins.
CONCLUSIONS
I t  is generally an advantage to isolate an oxidized 
(glyoxylyl-) polypeptide prior to oximation to avoid the 
necessity to use an excess of aminooxy component over 
the aldehydes coproduced during the oxidation reaction 
(formaldehyde from Ser, acetaldehyde from Thr, and 
formaldehyde from oxidation of the quenching agent 
ethyleneglycol). However, particularly when the N -ter-
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minal Ser/Thr residue to be oxidized is followed by Pro, 
we recommend “one-pot” oxidation-oximation to avoid 
possible formation of the cyclic isomer of the aldehyde 
described here.
We have not studied the biological properties of the 
heterocyclic isomer of the aldehyde. I t  might be interest­
ing as a scaffold for combinatorial chemistry of small (or 
even protein-sized) molecules, or for other purposes.
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Summary
Cholera Toxin B subunit (CTB), capable of binding to all mucous membranes in 
its pentameric form, is a potential carrier of mucosal vaccines. In our previous 
work we reported that the N-terminus of CTB, a threonine, could in principle 
undergo oxidation and oximation to form conjugates with a cascade of 
immunogenic peptides. In this study, we set up a model by chemically coupling 
CTB to a polyoxime that possessed five copies of influenzavirus-derived peptides 
displayed in comb-like form. The construct was reconstituted into pentameric 
form when eluted from a Superdex column after conjugation, and the pentameric 
nature of this CTB-like complex was confirmed by SDS-PAGE. GMrELISA assay 
showed that the binding properties of CTB conjugate were increased 4 - 5  fold 
over native CTB.
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Introduction
Cholera toxin, an AB5 hexameric protein composed of 5 identical B subunits and 
a single A subunit, is the primary enterotoxin produced by Vibrio cholerae 
bacteria, and is the causative agent of cholera infection. The B subunits of 
Cholera toxin (CTB) are the nontoxic binding components of the CT holotoxin [1] 
and function in pentameric form to specifically recognize the GMi ganglioside 
receptor present on the surface of mucous cells. It has been demonstrated in a 
large field trial that CTB afforded, when orally administered, protection against 
both cholera and enterotoxigenic E. co//-caused diarrhea [2]; and when 
conjugated to a poor immunogen and given orally, CTB showed the ability to 
dramatically increase the mucosal immunogenicity [3, 4]. This raised the 
possibility of using CTB as a potential carrier of mucosal vaccines. Holmgren, J. 
et al and other workers also reported that the physical coupling of foreign 
antigens to CTB is a very effective way of inducing such a mucosal immune 
response after oral vaccination [5, 6]. In our previous work we reported that the 
N-terminus of CTB, a threonine, could in principle undergo oxidation and 
oximation to form conjugates with a cascade of immunogenic peptides [7]. Here 
we explore a possible way to generate novel mucosal vaccines that are 
chemically coupled to peptide and reconstituted into a CTB-like complex in vitro. 
Since the mucosal immune response from oral vaccination is not restricted to the 
intestine but also partly disseminates to other mucosal tissues, this approach 
raises the prospect to use CTB as a vaccine carrier against infections in the 
intestinal as well as in any other mucosal tissues.
Synthetic peptides can serve as immunogens to induce antibodies, but a small 
linear peptide may not be effective as an immunogen because of the influence of 
protein conformation [8] and because of its lack of high molecular mass that is 
necessary for enhanced immunogenicity. One way to solve these problems is to 
create an artificial protein by coupling the antigenic peptide to protein carriers
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such as mucosal adhering proteins [e.g. CTB or LTB (E. coli heat-labile toxin B- 
subunit)]. In this way, a synthetic immunogenic peptide is attached to part of a 
protein carrier capable of localizing in a specific tissue (mucosa of 
gastrointestinal tract, for example). In order to enhance peptide immunogenicity 
further, it is possible to cross-link antigenic peptides to a synthetic core in a 
branched (radial or comb) manner. For instance. Tam [9] in 1988 designed an 
amide-linked branched artificial protein, a multiple antigenic peptide (MAP) 
system, to increase molecular weight. This is a macromolecule containing 
several copies of synthetic epitopes or protein antigens that are coupled to a 
peptide core matrix (based on lysine) by peptide bond formation. MAP directs the 
immune system to a specific response. As MAPs are entirely synthetic, they are 
in principle safer vaccines as they are free of replicative agents (viruses, DNA, 
prions) and endotoxin. Unfortunately, with this approach it is impossible to 
produce homogeneous artificial proteins due to inevitable side-reactions and 
coupling failures, and the wanted material, when the peptide epitope is longer, 
cannot be purified from the many impurities present with similar structure. One 
solution is to couple the pre-purified synthetic peptides to the MAP-core matrix by 
site-specific conjugation. Oximation chemistry is one of the mild and effective 
methods for such site-specific tagging that permits the modification of proteins 
without damaging their intricate structure [10].
In this study we set up a model by grafting a MAP system to the N-terminus of 
CTB. An antigenic peptide derived from hemagglutinin protein of inluenza virus 
was selected [11, 12]. We aim to use this model composed of polyoxime and 
mucosal carrier protein to study the possibility of attaching a cascade of 
immunogenic peptide to CTB and retaining or reconstituting its pentameric form.
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Materials and Methods
1. Reagents and chemicals
Unless otherwise specified, all solvents and reagents were obtained from Fluka, 
Buchs, Switzerland, were of analytical or higher grade and were used without 
further purification. All amino acids were purchased from Peptide Institute Inc., 
Japan. The resins were from Applied Biosystems, USA; Novabiochem, 
Switzerland, or Bachem, Switzerland. CTB was from Swiss Serum & Vaccine 
Institute, Bern, Switzerland. Water was repurified using a Milli-Q system 
(Millipore, Inc.).
2. HPLC and MS
Analytical RP-HPLC (reverse-phase high performance liquid chromatography) 
was performed using a column 250 x 4 mm i.d. packed with Nucleosil 300-A 5 
pm Cs particles at a flow rate of 0.6 ml/min and effluent was monitored at 214nm. 
Peptides were purified on a Cs semi-preparative column (250 x 10 mm i.d. 
Nucleosil 300-A 5 pm particle size) at a flow rate of 4 ml/min monitoring at 214 
nm, or purified on a Cis preparative column (210 x 25 mm i.d. Novapak 6 pm 
particle size) at 20 ml/min monitoring at 229 nm. Solvents used in RP-HPLC 
were as follows: A, 0.1% TFA (1 g TFA in 1 liter H2O); B, 0.1% TFA in 90% 
acetonitrile (1 g TFA mixed with 100 ml H20  and then brought to 1 liter with 
acetonitrile). Generally, the conditions used in analytical work were 5 min 
isocratic at 100% A followed by a linear gradient 2% B/min to 100% B, and in 
preparative work a shallower linear gradient (usually 0.5% B/min) was used. 
Components were collected manually at the detector exit, evaporated at room 
temperature, frozen and then recovered by lyophilization.
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Electrospray ionization mass spectrometry (ESI-MS) was performed in positive 
ion mode on a Trio 2000 machine or a Platform-ll instrument (both from 
Micromass, Manchester, England). Samples were introduced either at 2 pl/min 
(Trio) in an acidified solvent acetonitrile/water/AcOH (49.5 : 49.5 : 1) or at 10 
fil/min (Platform) in solvent acetonitrile/water/formic acid (49.9 : 49.9 : 0.2). 
MALDI-TOF mass spectrometry was performed in linear mode using sinapinic 
acid as matrix on a Voyager Elite machine (Perkin Elmer) equipped with delayed 
extraction. External calibration was performed on the electrospray machines 
using a solution of horse heart apomyoglobin, and on the MALDI-TOF machine 
using the mixture of peptides supplied by the manufacturer.
3. Synthesis of Peptides
The antigenic peptide sequences /VH2OC/-/2CO-KTYQRTRALV derived from 
Influenza virus [11, 12] were synthesized by Boc chemistry on 0.5 mmol Boc-Val- 
PAM resin (phenylacetamidomethyl resin, Perkin Elmer ABI division) using an 
automated solid-phase synthesizer (model ABI 430A, Applied Biosystems Inc.). 
Italic type denotes linker residues not present in the corresponding protein 
sequences. Side-chain protection of Boc-protected amino acid was Lys(2CIZ), 
Thr(Bzl), Arg(Tos). After chain elongation with Boc chemistry, the N-terminal 
Boc- protection of Lys was deprotected with TFA. The Boc-aminooxyacetyl 
(AOA) was attached to the Lys residue with an activated mixture solution (1.0 
mmol of Boc-AOA-OSu, 2-fold excess over the substitution of the resin in 5ml 
DMSO, 1 ml N-methylmorpholine) to form aminooxyacetyl precusor peptide.
The linker NH20CH2C0-Gly3-[Lys(Ser)]5-Gly-0H was synthesized manually on 
0.5 mmol Boc-Gly-PAM resin. After Boc deprotection, 5 cycles of coupling with 
Fmoc-Lys(Boc) and deprotection were performed by Fmoc-chemistry to form the 
linear polylysine core, followed by three cycles of Fmoc-Gly. The side-chain 
protection of Lys core was then removed, and Boc-Ser(Bzl) groups were 
attached to the core with an activated mixture solution (8 mmol Boc-Ser(Bzl)-
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OSu in 8 ml DMSO and 2 ml N-methylmorpholine), followed by Fmoc 
deprotection of the N-terminal amino group and attachment of a Boc-AOA group 
as above.
The resin and all other side-protection groups were cleaved with HF (0°C for 1 h 
in the presence of 5% p-cresol). Peptides were precipitated with cold ether, 
extracted with 50% acetonitrile, filtered and lyophilized. The crude peptides were 
purified by preparative HPLC and characterized by ESI-MS.
4. Preparation of Polyoxime conjugated to CTB
1 mg CTB, supplied as a lyophilized powder together with buffer salts, was 
dissolved in 1 ml water and isolated by gel filtration as the non-covalent 
pentamer on a Superdex 75 HR column (Amersham Pharmacia Biotech) at a 
flow rate of 0.4 ml/min. A phosphate buffer prepared by mixing NaH2PC>4 (0.25 M 
in H20 ) with Na2H P04 (0.25 M in H20 ) to obtain pH 7.0 and containing EDTA (to 
a final concentration of 1 mM) was used as eluent solution. The protein was 
concentrated by ultrafiltration (Centricon, Amicon, Beverly, MA, 10,000 Mwt cut 
off, precentrifuged twice with 1 ml of the phosphate buffer) to 400 pi. Methionine 
(50 pi, 0.2 M in H20 ) was added. N-terminal threonine was then oxidized for 5 
min by adding 25 pi sodium periodate (40 mM in H20). The reaction was 
quenched with 60 pi ethylene glycol (0.5 M in H20). After 4 min, 27.8 mg of 
aminooxyacetyl linker was added, followed by 50 pi acetic acid. 30 min later, 15 
pi of the reaction solution was removed for HPLC and ESI-MS, while 500 mg 
guanidine hydrochloride was added to the rest. After a reaction time of 16-18 h, 
the protein oxime was isolated by gel filtration and concentrated to 400 pi as 
before.
The five Ser residues on the linker NH2OCH2CO-Gly3-[Lys(Ser)]5-Gly-OH ligated 
to CTB were oxdized for 5 min by addition of 150 pi methionine (0.2 M in H20 )
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and 62.5 pi sodium metaperiodate (80 mM in H20). The reaction was quenched 
with 300 pi of 1,3-diamino-2-propanol (0.5 M in H20 , adjusted to pH 7.8 with 
acetic acid). 4 min later, 500 mg guanidine hydrochloride was added and the 
oxidized protein isolated again by gel filtration and concentrated by ultrafiltration 
to 400 pi. A second 400 pi of sample from a separate experiment was pooled at 
this stage. Then the powder of aminooxyacetyl influenza peptide (5.7 mg) was 
added to the pool (800 pi), followed by acetic acid to a final concentration of 4%. 
The reaction was left overnight, and the final product was isolated by gel filtration 
and the CTB complex was isolated in pentameric form. An aliquot of the final 
product was analysed by analytical HPLC and characterized by ESI-MS.
5. Concentration determination
CTB complex was analyzed by UV spectrophotometry (Ultrospec III, Pharmacia 
Biotech) scanning the region 240-320 nm, and the concentration was calculated 
according to the formula Absorbance28o = XI • C [C, concentration of the product; 
XI, total of molar absorptivity (e) of Tryptophan and Tyrosine in CTB complex: 
Absorptivity (e x 10‘3) of Tryptophan at 279 nm is 5.6, and absorptivity (e x 10'3) of 
Tyrosine at 275 nm is 1.4.]
6 .  S D S - P A G E
A sample of CTB complex was heated in a boiling water bath prior to the 
electrophoresis. 3 pi of heated and un-heated samples (1 pg/pl) of CTB complex 
were then loaded and run on a Homogeneous-20 Phast gel using a PhastGel 
System (Amersham Pharmacia Biotech) for approximately 30 minutes using a 
standard method. Two samples of commercial CTB (one native, one heated) 
were used as positive controls for the pentamer and monomer of CTB, and SDS- 
buffer served as negative control. A LMW Calibration kit of Protein Standards
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was used as a marker. The gel was then developed with silver staining 
automatically on PhastGel system for 90 minutes.
7 .  G M r E L I S A
A polystyrene 96-well ELISA plate was coated by incubation at 4°C overnight 
with 200 pl/well of 1.5pM Ganglioside GMi coating buffer (PBS). The plate was 
washed 3 times with PBS, and the additional binding sites were blocked by 
incubating plates with 200pl/well of a 2% (vol/vol) skim milk-PBS solution for 30- 
60 min at 37°C followed by washing 3 times with PBS. 100pl of the test samples 
was pipetted into a well immediately and the plates incubated at 37°C for 1h. The 
plate was washed again with PBS buffer, and 100 pi of 1:2000 goat anti-CTB 
was added to each well followed by incubation for 1 h at 37°C. After washing with 
PBS buffer, each well received 100 pi of a 1:24000 dilution of anti-Goat IgG 
(peroxidase) and the plate was incubated for 1h at 37°C. The plate was washed, 
then 100 pi of the chromogenic reagent (POD substrate) was added and the 
plate incubated 3-5 min to obtain a blue coloration. The reaction was finally 
stopped by addition of 100 pi of 1N H2SO4 (color change to yellow) and results 




1. "One pot” oxidation and oximation of CTB.
Oxidation and oximation of CTB with the linker molecuie NH2OCH2CO-Giy3- 
[Lys(Ser)]5-Gly-OH was performed under "one-pot” conditions as previously 
described [7]. The expected oxime CTB=NOCH2CO-Gly3-[Lys(Ser)]5-Gly-OH was 
purified by gel filtration, and one aliquot was analyzed by HPLC and 
characterized. Relative molecular mass found on ESI-MS was 12,938, close to 
the expected 12,937. Ser residues on the CTB linker complex were oxidized and 
the product purified by gel filtration. The oxidized protein possessed five 
aldehyde groups which were then oximated with aminooxyacetyl influenza virus 
peptide NH2OCH2CO-KTYQRTRALV (NH2OCH2CO-peptide) and isolated by gel 
filtration. One aliquot was analyzed by HPLC and characterized by ESI-MS which 
showed this product (relative molecular mass found, 19,236; theoretical, 19,234) 
to be the expected branched hybrid CTB=NOCH2CO-Gly3- 
[Lys(COCH=NOCH2CO-peptide)]5-Gly-OH. Generally, there is an advantage to 
isolate an oxidized N-terminal Threonyl or Seryl polypeptide prior to oximation, to 
avoid the necessity to use an excess of aminooxy component over the aldehydes 
coproduced from the oxidation reaction (formaldehyde from Ser, acetaldehyde 
from Thr, and formaldehyde from oxidation of the quenching agent 
ethyleneglycol). In our case, however, the N-terminal sequence of CTB is Thr- 
Pro- [13]. We demonstrated in our previous study that when N-terminal Thr-Pro- 
is oxidized the resulting aldehyde group 0=C H -C 0- can undergo a rapid 
cyclization and dehydration reaction through nucleophilic attack by the amide 
nitrogen of the third amino acid residue because of the rigidity of the proline ring 
which keeps the two reaction centers in proximity [7]. "One pot” oxidation- 
oximation was adopted here so as to avoid possible formation of the cyclic 
isomer of the aldehyde.
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2. CTB complex in pentameric form
CTB normally exists as a noncovalent pentamer which is necessary for CTB to 
specifically recognize the GMi ganglioside receptor present on the surface of 
mucous cells, but treatment with acid and organic solvents leads to quantitative 
dissociation to the monomeric form. A stepwise denaturation-renaturation 
process has been reported which allows CTB to regain its active form [14]. 
However, using this method in our previous study most of the CTB complex 
could not be obtained in pentameric form. The protocol was thus modified to 
obtain CTB=NOCH2CO-Gly3-[Lys(COCH=NOCH2CO-peptide)]5-Gly-OH from gel 
filtration in pentameric form. An aliquot of the eluate was taken for HPLC analysis 
and characterization, and the rest was kept for concentration determination by 
UV spectrophotometry and then used directly for the immunization assay. 1.5 ml 
of such pentameric solution was obtained in this way, with an absorbance after 
pooling of OD28o 0.068. Thus the concentration of CTB complex was determined 
as 0.81 pM by use of the formula OD28o = XI •  C (XI = 84 x 103 l/mol cm, total of 
molar absorptivity (e) of Tryptophan and Tyrosine in CTB complex; C, 
concentration of the product).
The pentameric form of CTB complex was further confirmed by SDS-PAGE. This 
was done using the standard method on PhastGel System (Amersham 
Pharmacia Biotech). Two samples of CTB complex pentamer (one was heated in 
boiling water for denaturation) obtained from gel filtration were detected on the 
electrophoresis gel, alongside two samples of commercial CTB (one was 
denatured) as positive control. The result (Figure 1) showed that the denatured 
CTB complex (Mr, 12,938) and its control, denatured commercial CTB (Mr, 
11,604), were close to the molecular marker 14,400, while the CTB complex (Mr, 
64,690) and native commercial CTB (Mr, 58,020) were close to molecular marker 
67,000. This indicated that the CTB complex like native commercial CTB was its 
noncovalent pentameric form and when denatured it can be dissociated into its 
monomeric form. Moreover, there were several parallel bands for CTB complex
Chen J. Page 114 Equivalent D
on the electrophoresis gel, which might be due to CTB complex lacking a copy of 
aminooxyacetyl peptide on one or more subunits. This loss can occur during gel 
electrophoresis. Our previous work [7] showed that the purified pentaoxime is not 
contaminated with species lacking a copy of aminooxyacetyl peptide.
3. CTB complex shows enhanced binding to GIVh
To determine the ability of the CTB complex to bind to the cholera toxin receptor, 
GMi ganglioside was bound to the surface of plastic microtitre plates and reacted 
with the CTB complex. ELISA assay was performed using a modified method 
from Svennerholm AM and Holmgren J [15]. Results were read at 450 nm using 
an ELISA reader, and a standard ELISA curve was obtained by testing the 
binding property of native CTB pentamer (Figure 2). The same GMi-ELISA 
experiment was also done on CTB complex, from which a ELISA curve was 
obtained (Figure 2). The curve of CTB complex was shifted to the left of the 
standard one and its value at 1.5 (OD 450 nm) showed that the affinity of CTB 
complex was 4 - 5  fold higher than that of commercial CTB, which may result 
from favorable comfomational change or stabilization of the CTB complex. This 
indicates that binding properties of the the CTB complex are at least as strong as 
those of the native CTB, in spite of the conjugation of antigenic peptides to its N- 
terminus. Since CTB complex pentamer possesses 5 x 5  antigenic peptides (see 
Scheme) it represents a useful candidate immunogen. This approach is general, 
and opens the way to create vaccine candidates using other immunogenic 
peptides.
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Conclusion
A polyoxime employing influenza virus-derived peptides as building block was 
successfully conjugated to the N-terminus of CTB, a potential carrier of mucosal 
vaccines, via a "one-pot” oxidation-oximation process. The construct was 
reconstituted into pentameric form when eluted from a Superdex column after 
conjugation, and this CTB-like complex was confirmed by SDS-PAGE. GMr  
ELISA assay showed that the binding properties of CTB conjugate were 
improved 4 - 5  fold over native CTB. Although we have not studied the 
immunogenicity of the CTB-conjugate, this general approach opens an 
interesting approach to create vaccine candidates using other immunogenic 
peptides.
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Figure Legends
Figure 1. SDS-PAGE of commercial CTB and CTB complex
CTB complex (Mr, 64,690) is in noncovalent pentameric form like its control CTB 
native (Mr, 58,020); while CTB complex (Mr, 12,938) when denatured by heat 
runs close to monomeric CTB standard (Mr, 11,604) produced by denaturation of 
the native pentamer. Negative control (loading buffer) and molecular weight 
markers are shown in the figure.
Figure 2. GMr ELISA of CTB
ELISA plates were coated with 1.5jliM Ganglioside GMi in PBS. Commercial CTB 
or CTB complex were tested for their binding properties using a modified method 
from Svennerholm AM and Holmgren J [14]. Result shows the avidity of CTB- 
complex pentamer are 40-50 fold higher than commercial CTB pentamer.
Scheme. Structure of CTB complex in pentameric form.
Five copies of CTB complex were pertamerized unconvalently and each subunit 
of CTB complex possesses a linear pentalysine linker and an antigenic peptide 
on the side chain of each lysine. Thus, the pentamer of CTB complex possesses 
5 x 5  copies of antigenic peptides.
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Summary
Peptide ligands that mimic natural ligands are often identified using the powerful 
phage display technique. However, the obtained ligands are usually of low- 
affinity (micromolar range) due to the high degree of conformational freedom and 
small number of contact residues within a short peptide molecule. One way to 
circumvent this drawback is to present several copies of the low-affinity peptides 
in a single multimeric molecule. Avidities (and bioactivities) can thus be greatly 
enhanced over the affinity or activity of the monomeric peptide. In this study, we 
prepared a series of multimeric constructs employing cell-targeting peptides as 
building blocks through oxime chemistry. These peptides were derived from 
phage display experiments selecting specific binding to pancreatic p-cells, and 
capable of eliciting uptake by the cells via receptor-mediated endocytosis. The 
multimeric molecules were taken up efficiently by the cells. Our results indicate 
that the avidity of the multimeric molecules for pancreatic receptors is high 
enough to elicit uptake. This study opens a promising way to develop novel 
chemical entities to specifically deliver therapeutic agents to control diabetes.
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Introduction
Progress in the transportation of peptides or proteins into cells in vivo may 
benefit from the transduction of large size molecules, which tends to be limited 
due to size and biochemical properties. For example, Schwarze SR and his 
colleagues described a 10-mer peptide derived from HIV, T A T 4 8 - 5 7 ,  that is 
capable of transporting conjugated peptides or proteins intracellularly into tissues 
and across the blood-brain barrier [1]. These peptides or proteins are internalized 
by cells via a so-called protein transduction process that does not involve 
endocytosis. This discovery opens a new methodology for biomedical research 
and for direct delivery of drugs into patients. However, an important limitation of 
this approach is secondary to the lack of cellular specificity of these types of 
transporters. Thus, adverse side effects on normal tissues limit their potential 
usefulness, a point that is particularly problematic for the treatment of chronic 
diseases like diabetes, for example.
Cell-type specific delivery might be achieved by successfully targeting cell- 
specific endocytotic receptors. Receptor-mediated endocytosis is indeed widely 
exploited in experimental systems for the targeted delivery of therapeutic agents 
into cells [2]. Endocytotic activity is a common property that has been described 
for many receptors including IgG Fc, somatostatin, insulin, IGF-I and II, 
transferrin, EGF, GLP-1, VLDL or integrin receptors [3-10]. Recently, the isolation 
of peptide sequences that direct efficient receptor-mediated endocytosis has 
been profoundly boosted by the use of phage display technologies [11 ]. Phage 
display libraries are extremely powerful tools that provide for a practically 
unlimited source of molecule variants including modifications of natural ligands to 
cell receptors [12] and short peptides [13]. Using this technology, evidence that 
cell-type specific receptors mediate endocytosis has been reported [14]. Similar 
libraries have been injected directly into mice and peptide sequences that show a 
13-fold selectivity for brain and kidney have been successfully isolated [15-16].
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The advantages of small peptide carriers such as those obtained using phage 
display libraries are numerous and include chemical synthesis and associated 
high quality and purity, low immunogenicity and potential highly efficient delivery 
to all cells in an organism [1]. Accordingly, peptide carriers have the potential to 
outscore more conventional transporters including liposomes or viruses for the 
efficient delivery of many macromolecules (see for example [17-18]). 
Unfortunately, the obtained ligands are usually of low-affinity (micromolar range) 
[19-20]. This may be due to the high degree of conformational freedom and small 
number of contact residues within a short peptide molecule.
If several copies of the peptide molecule with low-affinity binding sites are 
present in a single multimeric molecule, avidities (and bioactivities) can be 
greatly enhanced over the affinity or activity of monomeric peptide. IgM is an 
example of low-affinity protein, but, when presents in a pentameric form, the 
avidity is highly enhanced toward repetitive antigenic determinants present on 
the surface of bacteria or viruses [21]. Such enhancement (105-fold) occurred 
with the peptabody [22], a protein produced through recombinant DNA 
techniques. In this protein, the low affinity of polypeptides derived from phage 
libraries is compensated by its pentameric structure resulting in a high avidity 
towards their targets. Recently, Rose K [23] also designed such a molecule 
named "chemobody”. This is a synthetic molecule displaying multiple copies of a 
peptide subunit capable of binding non-covalently to a complementary structure, 
thus mimicking a major feature of the antibody molecule. The amino acid 
sequence of the binding peptide was identified using phage library techniques 
and the subunits themselves were assembled using oxime chemistry. To be able 
to bind through two or more subunits simultaneously, an appropriate spacer 
polyethyleneglycol (PEG) chain and a linker were also introduced, which are 
flexible, amphiphilic, non-immunogenic, and unsusceptible to proteases. Some 
reporter group such as fluorescein or biotin can also be introduced into the linker 
moiety of the Chemobody much more easily than into the Peptabody. Thus the
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Chemobody shows greater flexibility that renders it more convenient for biological 
use.
We previously created a model chemobody [23] that displayed 4 copies of a 
phage-derived peptide from influenza virus together with flexible 
polyethvleneglycol (PEG) linkers. In this study, we isolated by phage display 
panning a series of peptides that target pancreatic insulin secreting cells. We 
then prepared multimeric constructs employing these ceil-targeting peptides as 
building blocks through oxime chemistry with the aim of exploiting enhanced 
avidity through multivalent binding. These molecules potentiallly represent novel 
chemical entities to specifically deliver therapeutic agents to control diabetes.
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Methods
Materials and cell lines
Unless otherwise specified, all solvents and reagents were obtained from Fiuka, 
Buchs, Switzerland, were of analytical or higher grade and were used without 
further purification. All amino acids were purchased from Peptide Institute Inc. 
Japan. Resins were from Applied Biosystems, USA; Novabiochem, Switzerland, 
or Bachem, Switzerland. Water was repurified using a Milli-Q system (Millipore, 
Inc.). The insulin-secreting cell line pTC-3 [24] was used in the bioassay.
Phage preparation and enrichment procedures
A library of 3x108 independent phages displaying random 15-mer epitopes at the 
surface of the capsids was generated using standard procedure in the T7413b 
phage (Novagen). Phages were amplified then purified by polyethylene glycol 
(PEG) precipitation and finally resuspended at a concentration of 1010 infective 
particles per pi in Tris-EDTA buffer (10:1 mM, TE) as described [25]. Phages 
(1012) were added to cells in culture medium for 1 to 24 hours. Longer incubation 
times were preferred to favor isolation of phages that escaped proteolytic 
degradation in endocytotic vesicles. Following binding and internalization, cells 
were washed and non-internalized phages were destroyed by digestion with 
subtilisin (3mg/ml) [11]. Following extensive washing, internalized phages were 
then recovered by lysing cells in a buffer containing 2% deoxycholate, 10 mM 
Tris-HCI and 2mM EDTA, pH 8.0. Recovered phages were finally amplified in 
E.coli cells (XL-1-Blue) and purified as described above. This preparation of 
selected phages was then used for a second round of panning. Three to five 
sequential rounds were performed to obtain enrichment of specific phage-bearing 
peptide sequences.
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Peptides synthesis
The peptide sequence RRTK was obtained from the phage display experiments 
that showed the peptide consensus motif R/K-X-X-R/K for binding to pancreatic 
p-cells. Peptides modified as seen in Table 1 were synthesized manually on 0.5 
mmol Boc-Lys(CIZ)-PAM resin by Boc chemistry. Italic type denotes linker 
residues and space not present in the corresponding protein sequences. Several 
core structures used in this project were shown in Table 2. Synthesis was 
performed on 0.5 mmol methylbenzhydrylamine resin (MBHA resin) using Boc- 
chemistry.
All peptides were cleaved from the resin with HF (0°C for 1 h in the presence of 
5% p-cresol), precipitated with cold ether, extracted with 50% acetonitrile, filtered 
and lyophilized. The crude peptides were purified by preparative HPLC and 
characterized by ESI-MS.
Preparation of a Fluorescein linker
A fluorescein linker NH2OCH2CO-Lys(FITC)-OH was prepared according to 
Offord’s method [26]. In brief, 2 mmol of Boc-aminooxyacetyl (Boc-AOA-OSu) 
and 1.2 mmol of Ne-(TFA)-Lys were added into 3 ml of DMSO solution, and N- 
Ethylmorpholine was added until pH value 8-9. After incubation at room 
temperature for 15 hours and then at 37°C for 1 hour, the pH value was brought 
to 3.0 by carefully addition of glacial acetic acid under constant agitation. The 
product [Boc-AOA-Lys(TFA)-OH] was isolated on a preparative-scale HPLC and 
then dried. 4 ml water was added and then 0.44 ml piperidine (final concentration 
1 M) into the dried compound, which was incubated 4 hour at room temperature, 
followed by pH adjustment to 3.0 on ice. The mixture was diluted with 10 ml of 
0.1% TFA. The deprotected material (Boc-AOA-Lys-OH) was isolated by 
preparative HPLC and dried again. The latter was dissolved in 300 pi N,N- 
dimethylformamide (DMF), 40 mg fluorescein isothiocyanate (FITC) was added,
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and the mixture was adjusted to pH 8.0 with N-ethylmorpholine. After incubation 
for 15 hours in the dark, the product was purified by chromatography on a silica 
column [Kieselgel 60 (Fluka Chemie, Buchs, Switzerland), 1.5 x 20 cm] 
equilibrated in methanol/CH3CI (1:1, v/v). The excess FITC elutes in the flow­
through fraction, and a second yellow fraction containing the expected product 
was eluted with methanol/CHsCI (4:1, v/v). The solvent was removed by rotary 
evaporation, and the dried compound Boc-AOA-Lys(FITC)-OH was deprotected 
in TFA at a concentration not exceeding 20 mg/ml and left for 45 min at room 
temperature. The majority of TFA was then evaporated and drying was 
completed by lyophilization. The final product [AOA-Lys(FITC)-OH] was isolated 
by preparative HPLC and characterized by ESI-MS.
Alkylation of peptide ligands to the core
0.9 pmol of Cys core peptide (1.19 mg) was dissolved in 50 pi of acetonitrile and 
100 pi of water (peptide not fully soluble). A fresh solution of bromoacetyl peptide 
was prepared (3.6 pmol in 0.1 M sodium phosphate buffer, pH 7.0). Then the 
alkylation was started by mixing two solutions at room temperature in dark. After 
40 min, the product was purified on semi-preparative RP-HPLC, lyophilized, and 
characterized.
Periodate oxidation






Note, a bold letter denote an amino acid residue
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was dissolved, respectively, in 433 pi acetonitrile and 1.26 ml imidazole buffer 
(50 mM, pH 6.95, chloride counter ion). 113 pi of methionine (200 mM) was 
added. Then 17 pi of Nal04 (0.1 M in water) was added to start the oxidation. 
After 5 min the reaction was quenched by adding 40 pi of ethylene glycol (500 
mM in water). The product was purified on preparative HPLC and characterized 
by mass spectrometry.
Oximation
The aldehyde obtained by oxidation was then reacted with core 3 or 4 (containing 
an AOA group in each core), or AOA-Lys(FITC)-OH, to form an oxime. Oximes 1 
to 6 were obtained by this way (see Figure 1 and 2). For oximations with AOA- 
Lys(FITC)-OH, 0.129 pmol of oxidized construct was dissolved in 5 pi of 
acetonitrile and 200 pi of NaOAc buffer (acetic acid 0.57 ml in 100 ml of water, 
sodium acetate 0.82 g dissolved in 100 ml of water, mixed part of both until pH 
4.0). 0.516 pmol AOA-Lys(FITC)-OH (8.8 mg/ml in 100 pi acetonitrile and 100 pi 
of NaOAc buffer) was added into the mixture, followed by addition of acetic acid 
to a final concentration of 4%. For oximation with core 3 or 4, 3.8 pmol of 
oxidized peptide 3 or 4 was dissolved in 100 pi of acetonitrile and 200 pi of 
NaOAc buffer. 0.475 pmol core 3 or 0.237 pmol core 4 was added into the 
solution, followed by addition of acetic acid to a final concentration of 4%. After 
24 h reaction at room temperature, the product was purified on semi-preparative 
RP-HPLC and characterized by mass spectrometry.
Immunocytochemistry and fluorescence studies
Single phages isolated according to the enrichment scheme above were 
amplified. The phage peptides and synthesized oxime 1 -  6, respectively, were 
added and incubated for 24 hours with cells in culture medium. Medium was then 
washed off and cells fixed in cold methanol-acetone (1:1) for 5 minutes.
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Antibodies directed against the phage capsid or against biotin (peptides) were 
used with a fluorescein-conjugated (phage) or Texas Red labeled (peptides) 
secondary antibody. Classical fluorescence microscopic studies and confocal 




1. Construction of a novel phage system
Phage peptide libraries are traditionally constructed in derivatives of the 
filamentous phage M13. Peptide libraries are fused to the minor coat protein pill 
of the capsid that displays 1-5 copies of the peptide motif [13]. Alternatively, high- 
valent display is attained by using the major coat protein pVIII. These libraries 
however have not been optimized for the isolation of receptor-mediated 
endocytotic peptide sequences, because mono- or low-valent display of peptides 
is essentially insufficient for efficient uptake of such giant structures as 
filamentous phages and only a multivalent display allows for efficient uptake [11]. 
In addition, the internalization of receptor-bound ligands involves concentration of 
cell surface receptors in specialized areas of the plasma membrane and 
subsequent formation of clathrin-coated vesicles [27], and receptor-mediated 
internalization by these specialized and highly efficient structures is not expected 
to occur with the conventional M13 phages.
We therefore constructed a phage display library in the T7 415 phage system. 
This phage exhibits 415 copies of the displayed peptides within a reduced 
volume (capsid is ~50nM diameter).
2. Identification of binding peptide RRTK
We first panned the pancreatic (3-cell line (3TC-3 with our phage display library. 
Selective enrichment of the number of recovered phages is observed at each 
cycle of selection (Table 3).
Sequence analysis of 20 recovered phages at the final cycle of enrichment is 
presented in Table 4. Importantly, all sequences strictly obeyed a conserved
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consensus sequence of 5 amino acids (see below). This suggests the specific 
selection/enrichment of a conserved motif that directs efficient uptake of the 
phages.
Phage P1 was used for further analyses. Titration experiments indicated that as 
much as 10% of the initial P1 phage input could be recovered (Table 5).
Determination of the specificity of uptake was performed by titrating the number 
of recovered phages in 5 different cell lines. This indicates that P1 is uptaken by 
pTC-3 cells 10'000 to I'OOO'OOO fold more efficiently than by any other cell line 
tested (Table 6).
3. Generation of multiple transporter peptides
It is known that ligand peptides obtained from phage library are usually of low- 
affinity (micromolar range) [19, 20], and that their binding affinity or avidity can be 
enhanced by multimerize copies of the peptide molecule such as peptabody [22]. 
We here designed and synthesized a series of multimers (Figure 1 and 2) which 
displayed multiple copies (four or eight) of a p-cell specific peptide, RRTK, 
obtained from the phage library. A reporter group either FITC (fluorescein 
isothiocyanate) or Biotin was introduced into these multimer molecules.
The first construct (oxime 1, Figure 1) was built on a radial trilysine core (core 1) 
possessing a copy of RRTK peptide (peptide 1) at the tip of each of 4 branches. 
They were N-terminally conjugated through a thioether bond arising from a 
specific reaction between bromoacetyl and thiol groups. The trilylsine core also 
contained a PEG spacer and Ser capable of undergoing oxidation to generate an 
aldehyde, and thus a reporter group aminooxyacetyl-Lys(FITC) was introduced 
into the tetramer via oxime formation. HPLC and ESI-MS analysis revealed the 
desired product: Mr found 4289.31, Mr theoretical 4289.04. It was stable at acidic 
and neutral pH over 24 h.
Chen J. Page 135 Equivalent E
Oximes 2 and 3 (Figure 1) were formed in a similar way to oxime 1, but on oxime 
3 a two-unit PEG spacer was placed between the RRTK peptide and the core, 
and on oxime 2 the RRTK peptide was N-terminally conjugated to core 2 instead 
of core 1. Oxime 2: Mr found 4459.48, Mr theoretical 4460.19; Oxime 3: Mr found 
6708.29, Mr theoretical 6708.00.
Oxime 4 (Figure 2) was synthesized similarly to Oxime 3, but on its trilysine core, 
a Biotin group was attached directly via amide bond, instead of a FITC group as 
reporter. Mr found 6160.0, Mr theoretical 6160.3. Oxime 5 (Figure 3) was similar 
to Oxime 4, but its RRTK residues were all D-form. Mr found 6158.6, Mr 
theoretical 6160.3.
Oxime 6 (Figure 2) was synthesized as Oxime 4, but it possessed eight copies of 
RRTK peptide instead of four copies. Mr found 11646.1, Mr theoretical 11643.6.
4. Multimer transporter as novel chemical entities
Phage experiments indicated that the phage peptide RRTK was taken up 
specifically by pTC-3 cells (Table 6) via receptor-mediated endocytosis, though 
the efficiency of internalization was low, which might be due to its low-affinity 
binding (~x00 micromolar range). A serie of multimers displaying multiple copies 
(four or eight) of this peptide with a reporter tag, either FITC or Biotin, was built 
(Figure 1 and 2) in order to determine whether the uptake of the peptide could be 
enhanced.
Oximes 1 -  3 were first tested for their entry into pTC-3 cells. Fluorescence 
studies showed only oxime 3, a tetraoxime (tree design) employing four copies of 
RRTK peptide with 2 units of PEG space as building blocks, clearly bound to the 
receptors on the surface of pTC-3 cells and seemed to enter into the cells (Figure 
3). Whereas, oximes 1 or 2, tetraoxime tree-design or comb-design with four
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copies of RRTK peptide without any spacer, did not bind to the receptor and thus 
did not enter the cells. This may be due to the flexibility of PEG spacer in the 
oxime 3, which increases its binding properties to the receptors on the cells. 
However, the localization of the fluorescence peptide within the cells was not 
clear in this case.
We then designed oximes 4 - 6  (Figure 2) according to oxime 3 for an enhanced 
binding avidity and entry efficiency. The copies of the RRTK peptide was 
increased up to eight in oxime 6, whereas, the peptide was changed into its D 
enantiomeric form in oxime 5, because D-peptides had been demonstrated 
previously to possess an increased stability (and also lower immunogenicity, a 
point to consider when injecting peptides into animals [28]). Microscopic 
examination showed that the oxime 6 with eight copies of peptides entered cells, 
whereas the others did not (Figure 4) including one control. Texas Red labeled 
secondary antibody to the Biotin demonstrated that the octaoxime localized 
either inside cells as "vacuolar" structures, or at the cell membrane. Therefore, 
these results indicate that multimers, when the peptide copies are increased up 
to eight, greatly enhanced the avidity of the binding peptides and thus their 
transport efficiency.
Work in future
The structure of the multimeric molecules (chemobodies) needs to be further 
optimized to get higher avidity, and other reporters will be introduced as well for a 
more sensitive detection. The effect of conjugated inhibitor peptide will be 
investigated for specific delivery of therapeutic agents in order to control 
diabetes.
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Conclusion
To characterize multivalent binding peptides for enhanced avidity, we prepared a 
serie of multimeric constructs employing phage-derived cell-targeting peptides as 
building blocks through oxime chemistry, in which a reporter tag, either 
fluorescein isothiocyanate (FITC) or Biotin, was introduced. The selected peptide 
is specific for binding to the receptor on the surface of pancreatic p-cells and is 
then taken up by cells via receptor-mediated endocytosis. Microscopy showed 
that FITC-labelled molecules or Texas Red labeled secondary antibody to Biotin 
were taken up by the cell efficiently. Our results indicate that the multimeric 
molecules are of high avidity to the receptors and capable of entering cells 
efficiently. The study opens a promising way to develop novel chemical entities to 
specifically deliver therapeutic agents to control diabetes.
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Tables and Figures
Table 1. Synthetic peptide sequences modified from RRTK
Table 2. Core structures used in the project.
Table 3. Panning experiments using pTC-3 cells were performed as described in 
Methods, with 109 phages used at each step of the enrichment procedure. The 
number of phages recovered at 0°C (no endocytosis) is less 100, indicating that 
the background of extracellular (but not internalized) bound phages is extremely 
low in our conditions.
Table 4. Occurrence of phages recovered after three steps of panning in the 
pTC-3 cell line. 20 isolated phages were sequenced and grouped according to 
the sequence of the peptide displayed
Table 5. Titration experiments were performed with the phage P1 incubated for 
the indicated times with pTC-3 cells. Ratio of input/recovered phages is 
presented
Table 6. Phages (108) were incubated for 16 hours with the indicated cell lines, 
and the number of internalized and recovered phages was calculated. Control 
phages displaying an integrin internalization motif {Ivanenkov, Felici, et al. 1999 
ID: 305} showed a similar number (1-3x106) of recovered phages for all cell lines
Figure 1. Structure schemes for Oxime 1 - 3 .  The branching Lys residues of the 
cores are acylated on both alpha and epsilon amino groups with the N-terminus 
of RRTK peptide with or without a spacer. A reporter tag, FITC, together with a 
spacer is introduced into the core of each construct.
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Figure 2. Structure schemes for Oxime 4 - 6 .  The branching Lys residues of the 
cores are acylated on both alpha and epsilon amino groups with the N-terminus 
of RRTK peptide together with a spacer. A reporter tag, Biotin, together with a 
spacer is introduced into the core of each construct.
Figure 3. Fluoresence microscopy on a tetraoxime (oxime 3). Oxime 3 (tree 
design) employing four copies of RRTK peptide with 2 units of PEG spacer as 
building blocks was incubated with pTC-3 cells. After 1 hour, the construct clearly 
bound to the receptors on the surface of pTC-3 cells and seemed to enter into 
the cells.
Figure 4. Biotin assay on octaoxime (oxime 6). Oxime 6 possessing 8 copies of 
RRTK peptide was incubated with pTC-3 cells. Texas Red labeled secondary 
antibody to the Biotin demonstrated that the octaoxime localized either inside 
cells as "vacuolar" structures, or at the cell membrane, whereas, a control not.
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Table 1: Synthetic peptide sequences modified from RRTK
Peptide 1 BrCH2CO-RRTK-OH
Peptide 2 BrCH2CO-(peg-succ) 2-RRTK-OH
Peptide 3 H-S-(peg-succ)2-RRTK-OH (L-form)
Peptide 4 H-S-(peg-succ)2-RRTK-OH (D-form)
Table 2: Core structures used in the project.
Core 1 C4-K2K-K(succ-peg-S)-amide
Core 2 C-GGG-[K(C)]3-K(succ-peg-S)-amide
Core 3 (NH2OCH2 CO)4 -K2K-K(succ-peg-Biotin)-amide
Core 3 (NH2OCH2CO)8-l<4 K2K-K(GGG-Biotin)-amide
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Panning Phages recovered
1st c lx lO 3
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Oxime 3 Expected MS, 6708.00 Found MS, 6708.29
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Found MS, 6158.6
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